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ABSTRACT
Aims: The aims of this PhD research were to study the feasibility of
magnetoencephalography (MEG) measurements in Parkinson's disease
(PD) patients treated with deep brain stimulation (DBS) of subthalamic
nucleus (STN) and to cast light onto the effects of DBS on the electrical
activity of the brain. The ultimate aim was to gain a better understanding
of the unclear therapeutic mechanism of DBS.
MEG is very sensitive to magnetic fields and it is used as a powerful tool
to study noninvasively the brain's electromagnetic activity with an
excellent time resolution and reasonable spatial resolution. The
sensitivity, however, makes the measurements of patients using electrical
devices challenging because of confounding artifacts that partly or
completely obscure the measured signals. An artifact suppression method
called spatiotemporal signal space separation (tSSS) was developed
shortly before the beginning of this thesis project. One aim was to
investigate how tSSS works in the suppression of DBS artifacts in
patients undergoing DBS treatment. We also used MEG to study the
effects of DBS on spontaneous brain rhythms and on cortico-muscular
coherence (CMC) in PD patients. An accelerometer device detects the
three-dimensional acceleration during movements, including tremor. We
used this tool to study healthy volunteers to understand better the nature
of CMC.  
Methods: These studies were performed with a 306-channel MEG device
in the BioMag Laboratory in Helsinki University Hospital. The measured
MEG signals included evoked responses, spontaneous brain activity and
CMC in advanced PD patients that were being treated with DBS. A total
of 24 PD patients were included in the studies. CMC and
corticokinematic coherence (CKC) were also studied in 10 healthy
subjects. The effect of DBS was measured with DBS first being on and
then turned off as a crossover treatment. The patients thus served as their
own controls for the two conditions. Antiparkinsonian medication was
continued throughout the measurements. The Unified Parkinson's rating
scale (UPDRS)-III functional test was performed with DBS on and off to
correlate the MEG results with the clinical condition. 
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Somatosensory evoked fields (SEFs) were elicited by electrical 200-μs
square-wave pulses that were delivered to the median nerve. Auditory
evoked fields (AEFs) were elicited by 1-kHz sinusoidal 50-ms tones.
Spontaneous brain oscillations were recorded with the eyes closed and
open. For CMC recordings, MEG was recorded simultaneously with
surface EMG over the activated extensor carpi radialis muscle. The
healthy volunteers had an accelerometer sensor attached to their index
fingernail for the CKC measurements. The motor task was to hold
dorsiflexion of the wrist five times for one minute. Most patients and all
volunteers had brain MR images to combine with the MEG results. tSSS
was used for artifact suppression.
Results: tSSS reduced the DBS artifacts. This reduction enabled reliable
MEG signal analysis for most patients. Some residual artifacts remained
even after tSSS. Hence, the careful scrutiny of data was important even
after tSSS. 
The effects of DBS on the brain's electrical activity varied considerably
between patients. However, several statistically significant group effects
were observed. AEF N100m amplitude increased in the right hemisphere
for ipsilateral stimulation during DBS. When the DBS was on, the mu
rhythm amplitude of spontaneous MEG correlated significantly with the
UPDRS rigidity measures. The CMC was detected in 15 out of 19 PD
patients, as described previously in healthy control subjects. We did not
find a systematic increase in CMC in the 13 – 25 Hz band during DBS.
CKC could be recorded during the static wrist extension task in healthy
subjects. The source locations of CMC and CKC were overlapping and
their spectral profiles resembled each other.
Conclusions: tSSS is extremely useful in the artifact suppression of MEG
measurements of DBS patients. Despite this, MEG measurements of DBS
patients are still challenging and need exact planning of the experimental
setups and caution in the data analysis. DBS modifies cortical electrical
activity, and some of these modifications correlate with the clinical
improvement in PD. The accelerometer device accurately detects even
small movements during a hold task and may turn out to be a good
alternative to EMG for coherence calculations.
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1. INTRODUCTION
Parkinson's disease (PD) is a common progressive neurodegenerative
disease with clinical symptoms of bradykinesia, rigidity and resting
tremor. It is caused by a gradual destruction of the dopaminergic cells in
the substantia nigra. The brain oscillations have an important role in the
pathophysiology of PD. The disease is characterized by abnormally
synchronized beta band activity in the subthalamic nucleus (STN) and the
globus pallidus internal (GPi) (Bronte-Stewart et al., 2009). 
Levodopa has remained the most effective drug to relieve the motor
symptoms of PD. Long lasting use of high-dose levodopa probably gives
rise to daily motor fluctuations that can be delayed by using dopamine
agonists and /or monoamine oxidase (MAO)-B inhibitors. However, long-
term levodopa treatment eventually gives rise to unfavorable effects. The
most common symptoms are daily motor fluctuations such as “wearing
off” (the appearance of PD symptoms before the next levodopa dose) or
on-off phenomenon (phases of mobility alternating with immobility) and
dyskinesias. When severe drug resistant motor fluctuations and
dyskinesias appear, three treatments are available: 1) deep brain
stimulation (DBS), 2) levodopa-carbidopa intestinal gel (LCIG) infusion
or 3) apomorphine pump. DBS is a well documented treatment in
advanced PD (Krack et al., 2003; Deuschl et al., 2006; Weaver et al.,
2009; Schuepbach et al., 2013). Although DBS is an established treatment
for advanced PD, its precise mechanism of action is still unclear
(McIntyre et al., 2004; Montgomery Jr and Gale, 2008; Miocinovic et al.,
2013). 
The study of DBS action mechanisms in patients is challenging. All the
major functional brain imaging modalities have some limitations in
studying the effects of DBS treatments. Functional magnetic resonance
imaging (fMRI) and positron emission tomography (PET) imaging are
based on the changes in blood flow or circulation-distributed ligand
binding but measures of these parameters result in poor time resolution in
respect of brain oscillations. Haemodynamic measurements are also an
indirect estimation of neural activation. Moreover, the magnetic fields
generated in fMRI are an obvious risk to DBS patients. The magnetic
fields may damage or overheat the DBS device. PET and DBS devices do
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not interfere with each other but PET measurements  require the use of
ionizing radiation. This limits the serial measurements by such a method.
Electroencephalography (EEG) and magnetoencephalography (MEG) are
direct measurements of neural activity and are also safe for DBS patients.
The problems with these methods are associated with the electromagnetic
artifacts produced by DBS. A novel artifact suppression method,
spatiotemporal signal space separation (tSSS) (Taulu and Simola, 2006),
makes it possible to analyze MEG data that are contaminated by DBS
artifacts. When such artifact problems are solved, MEG is a useful non-
invasive tool for the study of the electromagnetic activity of the brain in
excellent time and good spatial resolution also in DBS patients. 
The studies that are summarised in this thesis investigated the feasibility
of tSSS in analyzing and evaluating DBS-treated PD patients measured
by MEG. The aim was to investigate the effect of DBS on the
electromagnetic activity of the brain. The evoked fields, spontaneous
brain activity and cortico-muscular coherence (CMC) of STN-DBS
treated Parkinsonian patients were measured. One study in healthy
subjects that utilized corticokinematic coherence (CKC) in addition to
CMC was also carried out to interpret better the results of CMC.
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2. REVIEW OF THE LITERATURE
2.1 Parkinson’s disease
2.1.1 Epidemiology of PD
Parkinson’s disease is a neurodegenerative disorder that is caused by the
destruction of dopaminergic cells in the substantia nigra. It is the second
most common neurodegenerative disease after Alzheimer’s disease and
the second most common movement disorder after essential tremor. PD
occurs predominantly in the elderly. Only 4% of PD patients get the
symptoms before the age of 50 years (Alves et al., 2008). The prevalence
of PD is about 0.5% for the 60 – 69 years cohort, and it increases up to
2% in people older than 80 years (Pringsheim et al., 2014) or even up to
4% (de Lau and Breteler, 2006). The age-adjusted prevalence of PD in the
beginning of 1990s in Finland was 166 per 100 000 population (Kuopio et
al., 1999). The incidence of PD increases as the population gets older.
This is especially the case in males as the male-to-female incidence rate
ratio increases (Kaasinen et al., 2015). There are approximately 15 000
PD patients in Finland.  
The aetiology of PD is unclear in most cases. Cigarette smoking and
coffee consumption are lifestyle factors that are consistently associated
with a reduced risk of PD. Other factors that have also been associated
with reduced risk of PD are exercise, the use of non-steroidal anti-
inflammatory medications, and use of dihydropyridine calcium channel-
blocking drugs (Goldman, 2014). Exposure to pesticides, particularly to
polychlorinated biphenyls (PCBs) is a possible risk factor for PD
(Goldman, 2014).  Mutations in seven genes are associated with either
autosomal dominant or recessive forms of PD or parkinsonism. PD or
parkinsonism are also suggested to be caused by changes in many
additional genes related e.g. to frontotemporal dementia or hereditary
ataxia. The known genetic mutations are very rare in most populations,
and thus explain probably fewer than 5% of all PD cases. (Puschmann,
2013) 
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2.1.2 Symptoms and disease progression in PD
Resting tremor (shaking), bradykinesia (slowness of movements) and
rigidity (stiffness, increase in muscle tone) are the well-known triad of
motor symptoms in PD. Postural instability and falls are common in
advanced PD. In addition to motor symptoms, PD patients also suffer
from non-motor symptoms such as hyposmia, problems in the autonomic
nervous system (causing e.g. postural hypotension and constipation),
sleep disturbances, depression and dementia (Seppi et al., 2011). Some of
the non-motor symptoms may precede the motor symptoms and diagnosis
by several years.
The progression rate of PD varies considerably between different patients.
In an individual patient, the motor symptoms progress quite constantly.
The tremor-dominant type of disease is thought to have a more favourable
prognosis than the hypokinetic variant (Marttila et al., 1991; Eggers et al.,
2012). Higher postural instability gait disorder (PIGD) score at baseline is
related to an increased mortality hazard ratio when adjusted for age, sex
and disease duration (de Lau et al., 2014) and also to more rapid cognitive
decline (Burn et al., 2006). PD increases mortality; the standardized
mortality ratio has been reported to range from 0.9 to 3.8; inception
cohorts showed a pooled mortality ratio of about 1.5 (Macleod et al.,
2014). However, about 10 % of patients have a benign course (Hely et al.,
1999). PD patients with dementia have an increased risk of mortality
compared with PD patients without dementia (Hobson et al., 2010; Willis
et al., 2012). Patients who do not develop dementia appear to have near
normal population mortalities (Hobson et al., 2010). Baseline
characteristics including the male gender, older age at diagnosis, higher
baseline Hoehn & Yahr stage, higher baseline UPDRS motor scores,
higher bradykinesia subscores and cognitive impairment were all reported
to be related to early mortality in PD (Oosterveld et al., 2015).
2.1.3 Physiology and pathophysiology of the basal ganglia in PD
The basal ganglia (BG), consist of the striatum, the globus pallidus (GP),
the substantia nigra (SN) (consisting of the pars pars reticulata and pars
compacta) and STN, are affected in PD (DeLong, 2000). The hallmark of
PD is the progressive loss of dopaminergic neurons in the SN pars
compacta and cytoplasmic inclusions (Lewy Bodies). The α-synuclein
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protein is the principal component of Lewy Bodies. The α-synuclein
might be a prion-like protein, being capable to adopt a self-propagating
conformation and causing neurodegeneration (Olanow and Brundin,
2013). Early neuropathological findings suggest that about 60% of the
dopaminergic neurons in the SN pars compacta will already have been
lost at the onset of motor PD symptoms (Schulz and Falkenburger, 2004).
The putamen is the most important afferent structure of the basal ganglia.
Two separate pathways originate from the putamen. One of them, the
direct pathway, inhibits the GPi and the other, the indirect pathway,
inhibits the globus pallidus external (GPe) which in turn inhibits the STN.
An excitatory projection connects the STN to the GPi. Inhibitory gamma-
aminobutyrate (GABA)-ergic projections from the GPi suppress thalamic
neural activity. The thalamocortical excitatory projections extend to the
cortex. 
Decreased dopamine action impairs the direct pathway from the putamen
to the GPi whereas the projection via the indirect pathway to the GPe is
overactive. These events lead to the disinhibition of GPi and to the
increased inhibition of the thalamocortical neurons. This is called the
classic pathophysiological model (Figure 1) of PD (Albin et al., 1989;
DeLong, 1990; Delwaide et al., 2000). 
Some data support the idea that the STN is another input station for the
BG. The hyperdirect pathway (Figure 1) projects from the cortex directly
to the STN. It bypasses the striatum, and goes further to the GPi. The
hyperdirect pathway is activated by the initiation of voluntary movement,
which leads to inhibition of large areas of the thalamus and the cerebral
cortex. Soon after, the signal from the direct pathway disinhibits these
targets and only the selected ‘motor program’ is run. Eventually, the
indirect pathway inhibits the targets thoroughly (Nambu et al., 2002).
It is also possible that other output recipients for the BG exist apart from
the cortex. BG may also project into the tegmentum, including
pedunculopontine nucleus (PPN). Signaling in this pathway probably
prepares the spinal cord neurons for cortical motor commands (Delwaide
et al., 2000).
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Figure 1. A simplified scheme of the basal ganglia-thalamo-cortical circuit. The black
arrows indicate inhibitory and the red arrows excitatory connections. The dotted arrows
represent weaker connections and the bold arrows stronger connections in PD than in
healthy subjects. Cell loss in the substantia nigra pars compacta (SNpc) leads to an
overactivation of the indirect, dopamine D2-receptor mediated movement-suppressing
pathway and an inhibition of the direct D1-receptor mediated movement facilitating
pathway. This leads to inhibition of the thalamus. The DBS sites that are targeted most
often in PD treatment are marked with a flash sign. 
GPe= globus pallidus external, GPi= globus pallidus internal, SNpc= substantia nigra
pars compacta, SNpr= substantia nigra pars reticulata, STN=subthalamic nucleus,
Vim=ventral intermediate nucleus
Untreated PD patients have been characterized to have abnormally
synchronized beta band (13 – 35 Hz) activity in the STN and the GPi
(Brown et al., 2001; Priori et al., 2004; Bronte-Stewart et al., 2009).
Coherence between the local field potentials (LFPs) that emanate from
STN and cortical sensorimotor oscillatory activity measured by MEG has
been reported (Litvak et al., 2010, 2012; Hirschmann et al., 2011). Beta
band oscillatory activity in the STN is decreased prior to movement and
increases during voluntary suppression of movements (Kühn et al., 2004).
Improvement of akinesia and rigidity, contrary to tremor, are associated
with reduction in STN 8 – 35 Hz activity (Kühn et al., 2006). STN 15-Hz
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oscillations have a tendency to correlate with the amelioration of rigidity
by medication, whereas oscillations around 25-Hz are associated with an
improvement in axial bradykinesia by DBS (Zaidel et al., 2010). Activity
and firing rate of STN neurons may increase with the progression of PD
(Remple et al., 2011). The beta band may be functionally divided. The
lower beta band (<20 Hz) might be more suppressed by dopaminergic
medication than the upper beta band (Priori et al., 2004). STN activity
may correlate in this lower beta band with the oscillatory activity in the
sensorimotor cortex (Fogelson et al., 2006). Moreover, worsening of PD
patient's motor symptoms is achieved by the stimulation of the STN at 10
H z (Timmermann et al., 2004), or in the 5 –10 Hz or 20 – 25 Hz
frequency bands (Fogelson et al., 2005).
2.1.4 Treatment
Currently, all treatment options relieve PD symptoms. No established
treatment to cure or stop the disease progression exists so far. The
medical treatment of PD is based on increasing dopaminergic activity in
the brain. Three main groups of medication are levodopa, dopamine
agonists and MAO-B inhibitors.
Levodopa was introduced in the late 1960s, and it is the most effective
medication for PD patients (Carlsson, 2002). Levodopa is the precursor of
the neurotransmitters dopamine, adrenaline and noradrenaline. Dopamine
per se does not cross the blood brain barrier as easily as levodopa does.
Aromatic L-amino acid decarboxylase, also known as DOPA
decarboxylase, converts levodopa to dopamine in the central and
peripheral nervous systems. Levodopa preparations include a peripheral
DOPA decarboxylase inhibitor or cathecol-O-methyloxidase (COMT)
inhibitors as adjuvants, which inhibit the conversion of levodopa to
dopamine before it crosses the blood brain barrier. The aim is to increase
dopamine concentration in the central nervous system while reducing the
side effects caused by the action of peripheral dopamine. Because
levodopa has a short half-life, it must be administered several times per
day particularly in advanced PD, where the dopamine storage ability of
the cells is decreased. After prolonged treatment with levodopa (about 5 –
7 years), severe side effects of the treatment become increasingly
common. The predictability of the treatment efficacy disappears; apart
from the wearing off-phase, the patient may have sudden off-phases.
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Severe dyskinesias may also occur with increasing frequency and
duration (Ferreira et al., 2013; Connolly and Lang, 2014). Infusion of
LCIG into the duodenum by duodenogastrostomy is used to circumvent
these problems (Olanow et al., 2014). The fluctuations in the levodopa
concentration, erratic absorption due to dosage, and problems related to
stomach emptying and nutrition are less severe with LCIG treatment.
Dopamine agonists are also important in the treatment of PD. Agonists
activate the receptors in a similar way as their physiological ligands even
in the absence of dopamine. The dose is taken once a day as a tablet
(ropinirole and pramipexole) or as a transdermal patch (rotigotine).
Dopamine agonists may postpone the appearance of motor fluctuations.
Dopamine agonists may cause side effects, especially in elderly patients,
who may get confused and experience hallucinations. They may also
cause impulsive control disorders, such as gambling, and hyper-sexuality
(Perez-Lloret, 2012). 
Apomorphine is the most potent, fast acting dopamine agonist. It has a
short half-life. Because of almost complete first-pass hepatic metabolism,
apomorphine is administered by subcutaneous injection (rescue dose) or
as a continuous infusion. Rescue injections for severe off-phase help
rapidly (3 – 30 min) and the effect may last for 20 – 120 minutes. An
apomorphine pump may be used in PD patients, who still have a good
response to levodopa and have frequent off-phases despite optimal peroral
drug therapy or use several apomorphine injections per day (Boyle and
Ondo, 2015). Currently, the apomorphine pump is not available in
Finland (2015).   
MAO-B inhibitors (selegiline and rasagiline) primarily reduce the
breakdown of dopamine and phenethylamine. The clinical effects of these
drugs are modest. They are often used at the onset of the disease, or in the
later phase when motor fluctuations occur. The MAO-B treatment needs a
concomitant endogenous or exogenous source of dopamine to be
effective. Amantadine, an antiviral agent, can be used to alleviate
levodopa-induced dyskinesias. Anticholinergic drugs are used rather
infrequently nowadays, because of cognitive side effects. (Ferreira et al.,
2013; Connolly and Lang, 2014)
The sequence of introduction of these medications for patients usually
starts with MAO-B inhibitors and/or dopamine agonists and then
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proceeds to levodopa, particularly in young patients. This is done to delay
the problems associated with long-term levodopa treatment. 
2.1.4.1 Surgery
2.1.4.1.1 Lesional surgery
Ablative surgery has been used as early as 1912 for the treatment of PD.
Leriche experimented with bilateral posterior cervical rhizotomy to
relieve parkinsonian symptoms (Hariz et al., 2010). The first surgical
treatments attempted to diminish tremor by reducing the motor function
by resections of the premotor or motor cortex, or by pyramidotomy and
pedunculotomy. With these procedures tremor might have been alleviated
but at the cost of motor functions, and other PD symptoms such as
rigidity were not reduced (Schiefer et al., 2011). The introduction of
stereotactic surgery (Spiegel et al., 1947) helped the progress of targeting
deep brain structures. Their importance was noticed by chance in 1952
when pedunculotomy was discontinued because of severe bleeding. The
artery was ligated, which resulted in an infarction of the medial GP and
an improvement of the patient's PD symptoms (Schiefer et al., 2011).
Electronic stimulation was also used in 1950s for verifying the target
prior to making lesions to treat psychiatric diseases (Hariz et al., 2010).
For example, the number of thalamotomies to treat PD in Helsinki
University Hospital was over one hundred per year in 1963-1966 and over
80 in 1967 and 1968, but the introduction of oral levodopa treatment
quickly decreased surgical treatment for PD (Laitinen, 1972).
2.1.4.1.2 DBS theraphy
The modern era of DBS therapy began in 1987 when Alim-Louis Benabid
and his team reported the efficacy of stimulation of the ventral
intermediate nucleus (Vim) of the thalamus for PD (Benabid et al., 1987).
The same team introduced the chronic stimulation of the STN to treat PD
(Limousin et al., 1995). The GPi was also tested as a promising DBS
target in mid 1990s based on previously reported efficacy of GPi lesions
on symptoms of PD (Siegfried and Lippitz, 1994). The DBS treatment has
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surpassed surgical lesion therapies as it is highly effective, reversible and
safe. DBS surgery is performed in two phases. First, the intracerebral
electrodes are implanted. Second, a subcutaneous generator and wires are
implanted in the surface of the chest but only when the stimulation
response turns out to be useful (Figure 2).
Figure 2. DBS device (with permission of Medtronic Inc.).
The most common present DBS targets for PD treatment are the STN,
GPi, Vim and PPN. Stimulation of the STN ameliorates several PD
symptoms and usually enables the reduction of dopaminergic medication.
Patients with advanced PD had quite similar improvement in motor
symptoms when STN and GPi stimulation were compared, but the
possibility for postoperative reduction of dopaminergic medication is less
likely for GPi stimulation (Follett et al., 2010). The GPi is also a target for
treating primary and some secondary types of dystonia. Vim stimulation
can be used in the treatment of PD when tremor is the main symptom, but
it does not improve other PD symptoms such as bradykinesia. Vim DBS
is also used to treat essential tremor. The PPN is an interesting target for
DBS for the treatment of axial symptoms and postural instability but the
treatment results are still conflicting (Follett and Torres-Russotto, 2012).
The PPN stimulators have not been implanted in PD patients in Finland
so far. 
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The DBS of STN is an established treatment for advanced PD when
motor fluctuations and dyskinesias are present despite optimal medical
treatment (Krack et al., 2003; Deuschl et al., 2006; Weaver et al., 2009).
DBS treatment was reported to be superior to optimal medication also in
patients with early motor complications (Schuepbach et al., 2013).
Originally it was supposed that high frequency stimulation inhibits the
target as similar effects were seen with ablative surgery. Nowadays, this
model is considered to be too simplistic. It may be that instead of ‘turning
down’ the STN activity, DBS treatment actually changes the neural
activity pattern of the STN (Garcia et al., 2003). High frequency DBS
may suppress the spontaneous activity in STN and generate a new activity
pattern in the gamma band (Garcia et al., 2005). 
Studying the LFPs of STN during STN-DBS has been demanding
because of electrical artifacts induced by the stimulation. Nevertheless,
suppressed subthalamic beta oscillations during STN-DBS have been
reported by some studies (Giannicola, 2010; Eusebio, 2011; Eusebio et
al., 2012). Stationary LFP beta oscillations during DBS have also been
reported (Rossi et al., 2008). STN-DBS probably decreases the excessive
beta activity in the STN and this may, at least in part, induce the reduction
of motor symptoms (Eusebio et al., 2012).
The effect of DBS may differ between neuronal soma and axon, as axons 
appear to be more sensitive to DBS (McIntyre and Grill, 1999). The 
minimum time needed to excite a neural element using half of the 
intensity that causes a threshold response (chronaxie) is around 30 – 200 
µs for myelinated axons and about 1 – 10 ms for cell bodies and 
dendrites. Thus, DBS activates efferent axons more easily than cell bodies
(Kringelbach et al., 2007). The strength-duration measurements in 
patients with GPi or Vim stimulators suggest that the primary targets of 
stimulation in both nuclei are large myelinated axons (Holsheimer et al., 
2000).
Studies that used rodent models of PD indicate that the cortex may play
an important role in the effect of DBS. Optogenetic inhibition or
excitation restricted to STN neurons was not as effective as direct motor
cortical stimulation in reducing Parkinsonian symptoms in mice with 6-
OHDA lesions (Gradinaru et al., 2009). Stochastic antidromic spikes that
emanate from STN during its stimulation in Parkinsonian rats alter the
firing rate of corticofugal projection neurons. This desynchronizes the
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excessive cortical beta band oscillatory activity and reduces the symptoms
(Li et al., 2012).
The optimal electrode contacts need to be selected for maximum
treatment efficacy. Stimulation parameters for DBS include amplitude
(voltage / current), frequency and pulse width. The effective voltage
ranges usually between 1 – 4 V. Stimulation for efficacious PD treatment
requires a relatively high frequency; usually 130 Hz or higher frequencies
are required. Lower frequencies, e.g. 60 Hz, may be sometimes beneficial
for ameliorating gait symptoms (Moreau et al., 2008). The stimulation
mode is usually monopolar but bipolar or combination of two adjacent
monopolar contacts can be applied. Moreover, an interleave setting can be
used. It is recommended that DBS would be programmed several times
during the first 6-month interval after the implantation (Bronstein et al.,
2011). Adjustments to stimulation and also switching stimulation 'on' and
'off' are done non-invasively by a programmer device.  
Tremor and rigidity may return within minutes after DBS has been
switched off in most patients. The entire therapeutic effect of DBS mainly
disappears within three hours after switching the stimulator off. After
turning the DBS off, the UPDRS motor scores increase to about 75% in
15 – 30 minutes whereas tremor subscores increase within 5 minutes.
Axial symptoms return slowly, within two hours after switching off the
DBS. (Temperli et al., 2003)
Symptomatic intracerebral haemorrhage (ICH) rates in functional
neurosurgery vary between 0 – 9% reported in patient series between
years 2001 – 2010; the overall incidence was about 2% (Zrinzo et al.,
2012). The rate of atraumatic device-related infection during the first year
after implantation was reported to be around 2% (Fenoy and Simpson,
2012). Clearly higher infection rates, of 10%, have also been reported
(Weaver et al., 2009). Transient postoperative delirium may be quite
common, occurring in 24% of the patients after the DBS operation (Krack
et al., 2003). Epileptic seizures have been reported soon after the
operation (Østergaard et al., 2002). During a six-month follow-up patients
with implanted DBS had more falls, gait disturbances, depression and
dystonia compared with the best medical therapy group (Weaver et al.,
2009). Weight increase, eyelid apraxia, dysarthria and dementia have
been reported with a permanent DBS treatment (Østergaard et al., 2002;
Krack et al., 2003).
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Indications for the DBS therapy include an advanced idiopathic PD that is
still responsive to levodopa. The patients with daily on-off fluctuations,
dyskinesias and intolerance to high doses of drugs required for symptom
control are good candidates for DBS. The drug-resistant tremor is also
suitable for DBS. The age of the patient should generally be below 70
years. It is also important that the patient has realistic expectations of the
treatment outcome. DBS will not cure nor stop the disease progression.
Contraindications for DBS treatment include clear dementia, general
operation contraindications (such as increased risk of bleeding or
anticoagulant treatment that can not be discontinued during the
operation), and devices such as defibrillators that could interfere with
delivered electrical pulses (Benabid et al., 2009). A slight cognitive
decline is acceptable for DBS candidates. Severe drug-resistant
psychiatric diseases (depression, psychosis) are also a contraindication for
DBS, but receded drug-induced hallucinations are not. Patients with
predominantly levodopa-resistant axial symptoms do not benefit from
DBS. 
Screening of advanced PD patients for DBS in Helsinki University
Hospital includes a levodopa challenge test, neuropsychological test,
brain MRI and psychiatric assessment when necessary. The preoperative
levodopa challenge test is done to verify the levodopa response; >30%
reduction in UPDRS III score is regarded as a positive response. Good
efficacy of levodopa is also indicative of a good response to DBS
(Kleiner-Fisman et al., 2006).  
Accepted indications for DBS in Europe are PD, essential tremor,
dystonia, epilepsy and obsessive compulsive disorder. Medically
refractory epilepsy has been treated with the bilateral stimulation of the
anterior nucleus of the thalamus (Fisher et al., 2010). Refractory
obsessive compulsive syndromes have previously been treated with
anterior capsulotomy; DBS targeting the anterior internal capsule
(Abelson et al., 2005) and nucleus accumbens (Sturm et al., 2003) has
been used as well. 
DBS electrodes have been implanted into the periventricular grey or in
the sensory thalamus to treat several types of chronic pain (Levy et al.,
1987) as off-label treatment. The best long-term results have been
obtained for the treatment of chronic low-back and leg pain and in
neuropathic pain of peripheral origin (Rasche et al., 2006). Other
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indications of DBS under research include e.g. Tourette's syndrome,
cluster headache, depression (Kringelbach et al., 2007) and Alzheimer's
disease (Laxton et al., 2010). 
2.2 MEG
Magnetoencephalography is used to record weak magnetic fields that are
produced by the brain's electrical activity when tens of thousands of
nearby neurons act synchronously. Neuromagnetic signals typically occur
over the 50 – 500 fT (about 10 – 100fT/cm) amplitude range. For
comparison, the steady geomagnetic field of the earth is about one billion
(109) times stronger. (Hämäläinen et al., 1993) 
Advantages of using MEG include complete noninvasiveness, an
excellent time resolution, in the range of milliseconds, and a good spatial
resolution. The spatial resolution can be a few millimeters at its best. The
spatial resolution achieved by MEG is better than that of EEG as the
magnetic fields are not distorted by the skull, skull breaches or by other
tissues, whereas electrical potentials are sensitive to such confounding
factors. Both spontaneous and evoked brain activity can be studied by
using MEG. The functional MEG data can also be combined with
anatomical information obtained by magnetic resonance imaging (MRI).
(Hämäläinen et al., 1993)
2.2.1 Neuronal basis
Activated neurons generate electrical currents and all electrical currents
create a magnetic field around them. The intracellular postsynaptic
currents in the apical dendrites of cortical pyramidal cells are the main
origin of the measured magnetic signals that emanate from the brain
(Hari, 1991). Postsynaptic potentials last longer than action potentials.
Apical dendrites of pyramidal neurons are oriented in parallel. Both these
facts enhance the summation of the magnetic fields (Hari et al., 2010).
Action potentials contribute to MEG signals only weakly as their
associated magnetic fields attenuate more rapidly than those of the
postsynaptic potentials as function of the distance. Moreover, action
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potentials of different cells are unlikely to synchronize (Lopes da Silva,
2010).
The dipole moments of a typical evoked magnetic field measured outside
the skull are in the order of 10 nAm (Hämäläinen et al., 1993). It has been
assumed that about 50 000 synchronously active cells are needed to
generate such magnetic fields (Lopes da Silva, 2010). During a typical
evoked response, about a million synapses must be active simultaneously
(Hämäläinen et al., 1993). 
The equivalent current dipole (ECD) is used to refer to the brain area that
contributes most to the measured magnetic field (see 2.2.3). Cortical ECD
does not exclude deep triggers, such as those related to thalamic inputs,
for the activation of the source area. Measured magnetic field patterns
may appear dipolar but this does not indicate that the source is a current
dipole. (Hari, 1991)
2.2.2 Instrumentation
As magnetic fields of the brain are very small, they require sensitive
instruments for their detection. This sensitivity is obtained by
superconductivity, which is at present achieved by bathing the sensors in
liquid Helium (the boiling point of Helium is 4.2 K = -269 °C). The
superconducting flux transformers detect the magnetic signal and conduct
it to the superconducting quantum interference devices (SQUIDs). The
SQUIDs in turn convert the magnetic flux into electric voltage. A special
container for the liquid helium, known as a Dewar is required to maintain
the temperature difference between the head and the sensors.  
Most MEG devices use gradiometers to diminish ambient noise. These
gradiometers detect the local gradients of the magnetic fields generated
by the brain but suppress more evenly distributed artifact fields that
originate in the environment. An axial gradiometer consists of a pickup
coil and a compensation coil above it (further away from the brain signal).
The coils are similar in size but are wound in the opposite directions. This
makes the gradiometer less sensitive to background noise as the
homogenous fields are effectively cancelled out. The signal that arises
near the pickup coil will cause a greater change of the field in the pickup
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coil than in the more remote compensation coil (Hämäläinen et al., 1993).
The two coils of a planar gradiometer are placed in the same plane. An
axial gradiometer obtains the maximum signal on both sides of a current
source. A planar gradiometer detects the largest signal over the source
(Hari, 1991). The magnetometer is a simple loop that picks up strongest
signals when positioned some centimeters away from the source. The
magnetometer has a sensitivity pattern that is similar to that of an axial
gradiometer (Hari et al., 2010). Nowadays, the sensor arrays cover the
whole scalp and the activity of the whole hemispheral cortex can be
recorded simultaneously. The Elekta Vectorview™ MEG device used in
these studies has 102 triple sensor elements, which include two
orthogonal planar gradiometers and one magnetometer. (Figure 3)
Figure 3. A subject seated under the MEG device in the BioMag Laboratory Helsinki
University Hospital.
The recorded signals from the brain are much weaker than the ambient
magnetic field alterations. Moving elevators and vehicles, televisions,
microwave transmitters, power-lines etc. produce significant ambient
magnetic noise. Therefore the MEG devices are usually housed in a
magnetically shielded room. The shielding decreases the disruptive
signals from outside the room. All possible artifact-producing objects,
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moving magnetic materials such as watches, phones, metal components
and entities like zips and jewellery must be left outside the shielded room.
Even the heart generates a magnetic field, which is two to three times
greater in magnitude outside the chest than the brain's magnetic field
outside the head (Hämäläinen et al., 1993).
2.2.3 MEG signal modelling
The calculations that are used to model sources of the MEG signal are
based on Maxwell's equations, which determine the resulting magnetic
field when the electric source current and surrounding conductivity
distributions are known. Analyzing measured magnetic fields to resolve
the electric source that generates them is called an inverse problem.
Theoretically there are an infinite number of sources that could give rise
to the measured magnetic field outside the scalp as the solution of inverse
problem. The number of possible solutions can be limited to meaningful
sources with proper prior knowledge of the source structure. (Hämäläinen
et al., 1993) Forward modelling from the calculated source and
comparison of the results with the measured magnetic fields is important
to evaluate the validity of the results. 
The external magnetic flux that is produced by the net intracellular
postsynaptic current is directed according to the right-hand rule. Only
currents with components that are tangential to the surface of a
spherically symmetric conductor generate a magnetic field that can be
detected outside the conductor. The corollary of this is that in brain
measurements the activity is detected mostly from the fissures of the
cortex. Luckily, the primary sensory areas of the brain are to a large
extent situated within the fissures (Hämäläinen et al., 1993; Hari and
Forss, 1999). 
A simple model that is often applied to MEG interpretation is a tangential
current dipole within a sphere. The sphere model produces a good enough
match to reality in the parietal and occipital areas of the brain, but it does
not illustrate the inferior surfaces of temporal and frontal lobes with
sufficient accuracy. Realistically shaped head models are needed for brain
localities that do not fulfill the presumption of sphericality. (Hämäläinen
et al., 1993)
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The current dipole that best fits the measured fields is the equivalent
current dipole (ECD). It is sought with a least-squares fit to the data. The
least-square approach seeks the parameter values that minimize the
difference between the observations and the predictions from the
corresponding model (Baillet, 2010). Multidipole models can be used to
represent complex sources as they can show time-varying source
strengths in several locations (Hari, 1991; Hari et al., 2010). The
goodness-of-fit (g) value reveals how much of the measured data are
explained by the model.
The minimum current estimate (MCE) is a distributed current estimate
with the constraint of a minimum norm. The MCE algorithm is based on
the l1-norm, which favours source estimates more focal than the l2-norm.
The l2-norm is used in minimum norm estimate (MNE). The frequency
domain minimum current estimate (MCEfd) enables localization of
multiple oscillating sources in a specified frequency band. The signal is
first transformed to the frequency domain by dividing it into sections
using a sliding window with 50% overlap and using the discrete Fourier
transform. The real and imaginary parts of the Fourier transformed signal
are used as inputs into the MCE algorithm, which gives current
distributions for real and imaginary current sources. The total current
estimate is obtained by summing the real and imaginary parts. Then the
total current estimates for all the sections are averaged over time, giving a
measure of the absolute current density for a given frequency. The MCE
results can be spatially normalized to a standard brain, which enables the
averaging over many subjects. (Jensen and Vanni, 2002) 
In beamforming methods, the brain volume is scanned by sequentially
applying spatial filters. A spatial filter sensitizes its output to match the
signal from a given brain area (Hari et al., 2010). It separates signals with
similar frequency content but different spatial locations. There should not
be highly correlated activations in the data analyzed by beamforming
method as they are explained by a single source (Baillet, 2010).
The tSSS method (Taulu and Simola, 2006) has been used in the studies
described in this thesis for suppressing the huge magnetic artifacts
produced by DBS. tSSS is effective in suppressing disturbances from
distant and near-by sources. First the measured signal is divided into two
spatially separate parts by the signal subspace separation (SSS): one
subspace depicts signals from the inside of the sensor array and another
one signals that arise outside the helmet (Taulu and Kajola, 2005).
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Thereafter, the temporally correlated components within these two
subspaces are recognized by principal component analysis and are
subsequently removed from the MEG data. The presumption is that the
real brain signals are so weak that they do not extend into the outer signal
source space. Moreover, the artifacts that arise near the sensor array can
be suppressed as they extend into both signal source spaces.
2.2.3.1 Evoked fields
The reactivity of brain activity to stimuli can be studied, inter alia, by
using MEG measurements. The MEG response to one stimulus is
normally difficult to separate from the background noise. Therefore
averaging, time-locked to the stimuli, is needed. Averaging improves the
signal-to-noise ratio and as a result the response induced by the stimuli
emerges. Often at least 40 – 100 averages are needed to achieve robust
evoked fields with an adequate signal-to-noise ratio (Mäkelä, 2014).
The evoked fields elicited by auditory, somatosensory or visual stimuli
are used to study the activity of the sensory cortices. For cognitive
studies, event-related fields averaged for randomly occurring stimuli,
which deviate from the standard stimulus sequence (oddball stimuli), can
be measured (Mäkelä, 2014).
The response to sensory stimuli consists of several deflections. The
earliest deflections may be separated from each other by only a few
milliseconds. These deflections can sometimes be related to separate
thalamocortical inputs to different cytoarchitectonic subareas or
intracortical transmission (Hari et al., 2010).
2.2.3.1.1 Auditory evoked responses
Auditory evoked fields (AEFs) are elicited by any abrupt sound or
alteration in an ongoing auditory stimulus. The most prominent deflection
is the N100m response, which peaks about 100 ms after the sound onset
or change and has source orientation generating a vertex negative (N)
deflection in EEG measurements (Hämäläinen et al., 1993). The response
is probably generated in the primary auditory cortex in Heschl's gyrus and
posterior to in the supratemporal plane (Hari et al., 2010). The exact
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source location depends e.g. on the tone frequency; auditory cortex is
thought to be organized tonotopically (Hämäläinen et al., 1993). The
AEFs are detected in both hemispheres after stimulus delivery to one ear.
The response is stronger and peaks earlier in the hemisphere contralateral
than ipsilateral to the stimulated ear. The source of N100m is located
about 1.5 cm more posteriorly in the left than right hemisphere (Elberling
et al., 1982). Stimulus characteristics modulate the AEFs. The amplitude
of N100m increases when the duration of the sound increases from 5 to
20 ms or when the interstimulus interval (ISI) is prolonged up to 8 – 10 s.
The N100m amplitude increases and latency decreases by increasing the
stimulus intensity up to 90 dB above the hearing level (Mäkelä and Hari,
1990). 
The AEFs have been studied in PD patients to investigate the preattentive
auditory processing. A significantly prolonged interhemispheric latency
difference of P50m and N100m AEFs was observed when the sound was
delivered to the left ear (Pekkonen et al., 1998).
The effects of DBS on auditory event-related potentials have been
measured by EEG. An auditory oddball paradigm revealed an increase in
the N100 latency between on and off DBS states. No significant change
was detected in the latency of the P300 response (Naskar et al., 2010).
Evidence of involvement of the STN in early-stage auditory processing
has been reported in PD patients. Evoked potentials elicited by
phonological stimuli were detected from the LFPs recorded in the STN.
The effect of levodopa on the subcortical auditory processing was limited
(De Letter et al., 2014).
  
2.2.3.1.2 Somatosensory evoked responses 
Human cortical somatosensory organization and processing can be
studied by recording somatosensory evoked potentials (SEPs) and
magnetic fields (somatosensory evoked fields, SEFs). The SEFs can be
elicited by tactile stimulation or by electric pulses to the peripheral
nerves. Electric stimuli are widely used as they elicit strong cortical
responses although they are not a natural way of activating the sensory
cortex (Forss et al., 1994b).
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Responses of healthy subjects to median nerve electrical stimuli are well
known. The first response, N20m, is elicited about 20 ms after the
stimulus in the contralateral primary somatosensory cortex (SI) in
Brodmann's areas 3b and 1. The next deflection, P35m, has approximately
the same location but an opposite polarity (Forss et al., 1994a). At about
90 milliseconds the secondary somatosensory cortices (SII) are activated
in both hemispheres. In general, contralateral SII responses were stronger
in amplitude and shorter in latency than the ipsilateral responses. Another
activation in the posterior parietal cortex close to the head midline occurs
at 70 – 115 ms in most subjects (Forss et al., 1994a). Stimuli delivered at
long and random ISIs generate stronger responses. Attention to the stimuli
(counting them) increases the response amplitudes (Mauguière et al.,
1997).
EEG studies of somatosensory evoked potentials in PD patients are not
congruent. Some studies have shown an amplitude decrease in the frontal
N30 component (Rossini et al., 1989) but other studies did not confirm
this finding (Garcia et al., 1995; Drory et al., 1998). No SEF
abnormalities were observed in PD patients with unilateral symptoms
(Mäkelä et al., 1993).
Bilateral DBS of both GPi and STN increases the frontal N30 response
amplitude but does not modify parietal N20 or P25 deflections; the effect
resembles that induced by apomorphine (Pierantozzi et al., 1999). A
transient obliteration of post-rolandic SEPs was observed some days after
DBS implantation in two patients when the stimulator was not yet on. The
amplitude of pre-rolandic deflections was preserved or slightly increased
after the commencement of continuous DBS (Insola et al., 1999).
Recordings of DBS effects on SEPs were taken after discontinuing DBS
in both studies. 
2.2.3.2 Spontaneous brain oscillations 
Brain electrical activity is characterized by rhythmic oscillations, with
frequencies that range from infraslow (below 0.1 Hz) frequencies up to
600 Hz oscillations (Mäkelä, 2014). The most studied brain rhythms
include occipital alpha and rolandic mu rhythms. Sources of temporal 10-
Hz oscillatory activity (“tau rhythm”) are located near the sources of
auditory evoked responses (Hari et al., 1997). These rhythms can be
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modified separately by voluntary actions such as closing the eyes, or
making hand movements.
2.2.3.2.1 Occipital alpha rhythm
The peak frequency of the occipital alpha rhythm is around 10 Hz. Its
sources, detected by MEG, cluster around the parieto-occipital sulcus and
around the calcarine sulci. The occipital alpha rhythm is suppressed by
opening the eyes. Dampening of the occipital alpha rhythm also occurs
after visual stimulus and even after mental imagery of an image. (Hari et
al., 1997)
2.2.3.2.2 Mu rhythm
The rolandic mu rhythm consists of frequencies at about 10 and 20 Hz;
the combination of these frequencies creates the typical 'comb-like' shape
of these oscillations. The mu rhythm is dampened by movement, by
preparing to initiate a movement or by imagining a movement. Tactile
stimuli suppress the mu rhythm (Salmelin and Hari, 1994). Practically all
healthy subjects display MEG oscillatory activity at these frequencies, at
least after executing a movement (Hari et al., 1997). 
The rebound after movement-induced suppression is faster and stronger
for the 20 Hz component (Hari et al., 1997). The sources of the 20-Hz
signals tend to cluster anterior to the sources of the 10 Hz signals. The 20-
Hz oscillations are presumed to be generated in the sensorimotor cortices
whereas the 10-Hz rhythm may be predominantly generated in the
somatosensory region (Salmelin and Hari, 1994).
2.2.3.3 Coherence
Coherence is a measurement of the linear dependence of two signals and
describes the relationship between two time series. It is defined as the
magnitude of the squared cross spectrum of the two signals normalized by
the power spectra of both time series at a given frequency bin. The
coherence values vary between 0 and 1, and reflect the consistency of the
phase difference between the two time series; 0 indicates no resemblance
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between the two time series, whereas 1 indicates a perfect linear
association. The classical coherence measures have some limitations. For
example, data must be stationary. Coherence between two signals can
also result from a common input from a third signal. Coherence is also
sensitive to both the amplitude and phase dynamics. (Gross et al., 2010) 
2.2.3.3.1 CMC
The first observations that muscle discharge is likely to be rhythmic was
made 200 years ago by William Wollaston. Later, in the beginning of 20th
century, Hans Piper described a modulation of motor unit discharge at
around 40 Hz. The first evidence supporting a central origin for this motor
unit synchronization was presented in the early 1990s. (Grosse et al.,
2002)
CMC is thought to indicate the co-ordination between cortex and muscle
during static motor activity. The CMC activity is estimated between
simultaneously recorded MEG / EEG and by electromyography (EMG)
signals. There is a consistent phase lag between the motor cortex (M1)
and EMG signals (M1 activity preceding EMG) and it is therefore thought
that the motor cortex drives the spinal motoneuron pool (Gross et al.,
2000). The cortical rhythm probably tunes the activity of a population of
motor units (MUs) instead of driving individual MUs (Hari and Salenius,
1999). Recently, sensory feedback from the periphery has also been
suggested to contribute to CMC (Witham et al., 2011). The beta
frequency band (13 – 35 Hz) of the brain signals is most often coherent
with EMG during the maintained motor task. Signals in the alpha (around
10 Hz) or gamma (40 – 50 Hz) frequency bands display coherence only
occasionally (Conway et al., 1995). The CMC in the gamma band is more
obvious during strong muscular contractions (Brown et al., 1998). The
CMC sources for hand and foot muscle activation display a crude
somatotopic organization in the contralateral motor cortex. Nevertheless,
there is no difference in the sites of maximum coherence between the
various upper limb muscles (Hari and Salenius, 1999). 
The level of coherence during a precision grip task is influenced by the
task features (Kilner et al., 2000). Precise motor performance may
(Kristeva et al., 2007) or may not (Johnson et al., 2011) correlate with
high CMC values. Divided attention during muscle activation decreases
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CMC amplitude (Kristeva-Feige et al., 2002; Johnson et al., 2011). The
intra-session reproducibility of CMC strength and peak frequency has
reported to be good (Pohja et al., 2005).
The 40-Hz Piper rhythm, detected during strong wrist extension was
replaced in PD patients by pulsatile muscle activity of about 10 Hz during
an off medication period. Subsequent dopaminergic medication restored
the piper rhythm, indicating the importance of the proper functioning of
pallidal projections to the motor cortex for normal muscle discharges.
(Brown, 1997.)
 
The CMC in the 15 – 30 Hz band during isometric contraction was found
to be weaker in PD patients withdrawn from levodopa treatment
compared with healthy controls. Levodopa treatment was also reported to
increase the CMC in PD patients (Salenius et al., 2002). However, CMCs
of the de-novo PD patients or early-stage PD patients had similar CMCs
compared with healthy controls (Pollok et al., 2012). The CMC amplitude
between sensorimotor MEG signals and the muscle of the tremorous hand
in the range of 10 –30 Hz increased during STN-DBS in three PD patients.
This increase correlated with decrease of UPDRS tremor points (Park et
al., 2009). A study on eight PD patients found that the average EEG-EMG
CMC in the 15 – 20 Hz range was slightly increased eight days after DBS
implantation when DBS was switched on (Weiss et al., 2012). 
Parkinsonian resting tremor also creates CMC at the tremor frequency
and at its harmonics (Volkmann et al., 1996; Timmermann et al., 2003).
MEG recordings and data analysis with dynamic imaging of coherent
sources (DICS) suggest a network comprising primary sensorimotor
cortex, premotor cortex, cerebellum and thalamus that are activated
during the resting tremor (Schnitzler et al., 2006). The oscillatory network
observed in healthy subjects with mimicked resting tremor is to a large
extent similar to that observed in PD patients during tremor (Pollok et al.,
2004). In an MEG study of one patient, DBS suppressed resting and
postural tremor and CMC at 4 -Hz tremor frequency and at 8 Hz
(Connolly et al., 2012).
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2.2.3.3.2 CKC
Corticokinematic coherence can be estimated between simultaneously
recorded MEG and accelerometer signals from a moving body part. The
CKC is found at the movement frequency and its first harmonic
(Bourguignon et al., 2011; Piitulainen et al., 2013a, 2013b), and sources
of CKC are localized in the sensorimotor cortex contralateral to the
moving body part (Bourguignon et al., 2011). A comparison of active and
passive finger movements suggested that the CKC that arises during
repetitive finger movements is driven mainly by proprioceptive afferent
input to the primary sensorimotor cortex (Piitulainen et al., 2013b).
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3. AIMS OF THE STUDY
The aim of this study was to explore the effects of DBS on the brain
electrical activity in advanced PD patients with the ultimate aim of
gaining a better understanding of its therapeutic mechanisms. The patient
data made evident the need to understand better the physiological
mechanisms of CMC. Study IV in healthy volunteers describes the first
step in this endeavour. The specific goals were:
1. Confirm that the MEG data obtained from DBS treated patients is
amenable to analyses after artifact rejection by tSSS. Previously well
known SEFs and AEFs were analyzed to see if DBS artifacts can be
removed efficiently and if the remaining signals contain physiologically
valid data (Study I).
2. Study the effects of DBS on spontaneous brain rhythms in PD patients
(Study II).
3. Investigate the effect of DBS on CMC in PD patients (Study III).
4. Compare CMC and CKC during static muscle contraction in healthy
volunteers to gain a better understanding of the physiology of CMC
(Study IV).
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4. MATERIALS AND METHODS
4.1 Patients and Subjects
A total of 24 advanced PD patients who were treated with STN-DBS
(Kinetra or Activa PC Neurostimulators, Medtronic Inc, Minneapolis,
MN, USA) were recorded by MEG in studies I – III. 
The patients were recruited from the Department of Neurology in
Helsinki University Hospital. The mean age of the patients was 59 years
(± 10 years). The patients had had their diagnosis about 13 years (± 5
years) before DBS implantation. Their mean UPDRS motor III scores
during the MEG recordings were 22.7 (± 11.5) when DBS was on and
36.7 (± 17) when DBS was off (p < 0.001). The mean levodopa
equivalent daily dose (LEDD) was 1020 mg (± 495 mg) (Table 1). The
following formula was used to calculate the LEDD: 100 mg levodopa =
130 mg controlled-release levodopa = 70 mg levodopa + COMT inhibitor
= 1 mg pramipexole = 5 mg ropinirole (Mamikonyan et al., 2008) = 4 mg
rotigotine (Poewe et al., 2007). 
Study I reports data from 12 patients. The same patients participated in
Study II; one of them was excluded because of missing UPDRS scores
when the DBS was off. Study III reports data from 19 patients, 7 of whom
had also been included in Study I. The other 12 patients had not
participated in any previous study. Four patients of Study I were excluded
because their MEG measurements were taken less than two months after
the DBS implantation. 
All patients used their regular antiparkinsonian medication during the
MEG recordings. The UPDRS III motor scores in studies I– III were
determined before the patient entered the shielded room with DBS on and
when the patient exited the shielded room after the measurement when the
DBS had been turned off. 
Data of some patients measured with MEG were excluded from the
reports. In one patient, strong artifacts saturated the MEG amplifiers
completely and no brain signals were recorded. In another patient,
localization of the head position failed. A few patients did not tolerate the
measurements during the DBS off phase. Another subgroup of patients
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was excluded due to missing UPDRS scores or small, ineffective DBS
voltages. 
Table 1. Patient characteristics.
















1 M 59 14 25 23 31 2160 I – III
2 M 59 11 24 17 20 1290 I – III
3 F 60 7 25 39 49 620 I – III
4 M 68 10 7 27 37 490 III
5 M 36 8 4.5 26 71 210 III
6 M 43 10 6 21 60 570 III
7 M 63 18 5 20 21 1550 III
8 M 57 16 6 19 1260 III
9 F 68 14 5 44 69 530 I – III
10 M 49 9 25 16 25 1600 I – III
11 M 42 6 6 6 17 1660 III
12 F 64 25 7.5 18 40 650 III
13 M 68 21 17 30 1650 I, III
14 M 58 12 24 33 38 1200 I – III
15 M 64 9 6.5 22 38 560 III
16 F 66 18 6 10 20 850 III
17 M 47 8 6 6 45 460 III
18 M 50 14 12 18 24 1080 III
19 M 71 8 6 12 27 820 III
20 F 67 11 2 12 14 1120 I – II
21 F 55 19 1.5 22 60 1170 I – II
22 F 65 10 1 16 23 1060 I – II
23 M 60 16 0.5 34 46 1500 I – II
24 F 75 13 1.6 50 50 510 I – II
In Study III, subgroup analyses were done for 10 patients with more than
30% decrease in UPDRS III motor scores when DBS on to study the
robust effect of DBS on motor symptoms.
37
Ten healthy subjects (4 female, mean age 30 years, range 22 – 58 years)
participated in Study IV. 
The research protocols for all four studies were accepted by the Ethics
Committee of the Department of Neurology, Helsinki University
Hospital. All patients and subjects gave their informed written consent.
4.2 MEG measurements
The MEG was recorded in the BioMag Laboratory of Medical Imaging
Center, Helsinki University Hospital by a 306-sensor Vectorview™
neuromagnetometer (Elekta Neuromag®, Elekta Oy, Helsinki, Finland)
with 204 planar gradiometers and 102 magnetometers. The MEG device
was situated inside a magnetically shielded room (Euroshield Ltd., Eura,
Finland). 
The alignment of the MEG and magnetic resonance imaging (MRI) co-
ordinate systems was done by placing the head position indicator coils
with respect to head landmarks using a 3-D digitizer (Fastrak®, Polhemus,
Colchester, VT) and activating the coils before each measurement. Each
patient's head position with respect to the MEG helmet was determined at
the commencement of recording in studies I–III. The head position of
healthy subjects was recorded continuously in Study IV. 
The patients were recorded first with DBS on and then with DBS off.
This sequence was reversed for one patient. An experienced nurse was in
the shielded room with the patient to monitor their welfare and
performance and control alertness.
The auditory stimuli were delivered by Presentation software and directed
through plastic tubes to the patient. The delay caused by the tubes was
taken into account in the analyses. AEFs were elicited by sinusoidal 1-
kHz 50-ms tone pips. Stimulus intensity was about 60 dB above the
ambient noise. The sounds were delivered to each ear separately. We
confirmed that the patients heard the tone pips clearly. 
Electrical stimulators (Digitimer Ltd, model DS7A, Welwyn Garden City,
England) were used to produce electrical 200-μs square-wave pulses for
38
median nerve stimulation. They were delivered alternately to both median
nerves with intensities sufficient to elicit a clear but non-painful thumb
twitch.  
Visual checkerboard stimuli were also presented to the patients but the
results were not analyzed further. Auditory, somatosensory and visual
stimuli were displayed in random order in one stimulus sequence. The
time between subsequent stimuli was 600 ms. The minimum ISI was 0.6 s
and the mean ISI 5.5 s for each stimulus type.
Spontaneous MEG was recorded first with the eyes closed for three
minutes and then with the eyes open for five minutes both when DBS was
on and off.
Bipolar EMG recording were taken by attaching surface electrodes over
the extensor carpi radialis muscle. The EMGs of patients were recorded
from the more affected upper limb. The EMGs were recorded from both
forearms of heal thy volunteers . Hor izonta l and ver t ica l
electrooculography (EOG) was recorded to enable exclusion of eye
movement and blink artifacts. The recording passband was 0.03 – 330 Hz
and the sampling rate 1012 Hz for MEG, EMG and accelerometer signals.
The patients (Study III) and subjects (Study IV) were requested to extend
their wrist (dorsiflexion) five times for one minute. Each dorsiflexion was
separated by a 20-s rest period. The patients in Study III extended the
more affected hand. Volunteers in Study IV extended first the right hand
and then the left hand.
Postural tremor in Study IV was recorded using an accelerometer
(ADXL335 iMEMS Accelerometer, Analog Devices Inc., Norwood, MA,
USA). The movement sensor was fixed onto the fingernail of the index
finger of both hands. The accelerometer measures finger acceleration in
three orthogonal directions. 
4.3 Data analyses
DBS produced strong magnetic artifacts which were suppressed by the
tSSS method (Taulu and Simola, 2006) (Figure 4). An 8-second time
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window and a subspace correlation limit of 0.9 (Studies I, III and IV) or
0.8 (Study II) were applied.
The EMG in Study III was rectified before subsequent analyses. The
EMG in Study IV was not rectified.
The sensor positions were equalized by applying the multipole-based
method (Taulu et al., 2005) implemented in Elekta MaxFilter™ software
to enable the comparison between DBS on and off conditions in Study III.
4.3.1 Dipole modelling
Source analyses in Study I were done with an ECD model. The applied
spherical head model was fitted into the individual brain MRIs. Two
patients did not have a brain MRI. For them, the x-, y-, and z-co-ordinates
of 0, 0, 40 mm were used as sphere origin. The responses were averaged
from tSSS-processed raw data. AEFs were filtered with a 1 – 40 Hz
passband. For SEFs, the passband was 0.5 – 100 Hz.
The sources of the AEF N100m were sought from hemispheres
contralateral and ipsilateral to the stimulated ear. A subset of 11 – 15
gradiometer pairs around the maximum response was used in the source
localization. ECDs were fitted with a 1-ms interval sequentially 80 – 130
ms after the stimulus onset. Co-ordinates of the best dipoles (in terms of
source strength and goodness-of-fit) for auditory cortex source for each
patient were selected and used to calculate time-varying N100m source
strengths with DBS on and then off.
The sources of SEFs were estimated by sequential ECD fitting with 1-ms
intervals 15 – 80 ms after the stimulus. Twelve to fourteen gradiometer
pairs around the maximum response were used to calculate the SEF
sources in the primary somatosensory cortex (SI) contralateral to the
stimulus. The ECDs were determined when DBS was on and then off.
Co-ordinates of the best dipoles were selected for each patient with the
same criteria as in AEFs. The source strengths and latencies of N20m and
P60m were determined from dipole strength versus time curves for both
the DBS on and off conditions.
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Figure 4. Spontaneous recordings of MEG from the left hemisphere and EOG recording
when DBS on. A before tSSS; B after tSSS. Data from Study I.
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4.3.2 Analysis of spontaneous brain activity
The sources of oscillatory activity in Study II were localized by the
frequency domain minimum current estimate (MCEfd) (Jensen and
Vanni, 2002). The fast Fourier transform (FFT) spectra were calculated
from the signals to detect any interesting spectral ranges. The FFT length
was 512 samples corresponding to a frequency resolution of about 2 Hz.
The spectral peaks were carefully inspected. Although the tSSS
suppressed most DBS artifacts, some narrow interference peaks remained
in the spectra.  The lowest detected artificial peak was at 20.7 Hz. Signals
at spectral ranges of 2 – 6 Hz, 6 –10 Hz, 12 – 20 Hz and 21 – 30 Hz in the
sensorimotor region were selected for the study. The 20 – 21 Hz band was
omitted from further analyses because of the spurious artifact peak at 20.7
Hz. The individual mu rhythm frequency band around 10 Hz (peak ± 2
Hz) was examined as well. The source amplitudes in the occipital region
were studied from a frequency band around the individual peak alpha
frequency ± 2 Hz. 
In MCEfd, the data are transformed to a frequency domain using the
discrete Fourier transform (DFT). A DFT segment size of 4096 samples
was used to obtain 0.25 Hz frequency resolution. The minimum current
estimate (MCE) was made for the transformed data (Uutela et al., 1999).
A region of interest (ROI) was outlined over the active source areas. The
ROI was fitted automatically for each subject. The total source amplitude
was computed from a weighted sum of all active voxels of the ROI. The
weighting function was a three-dimensional Gaussian, with a magnitude
of 1 at the center of the region and 0.6 at the edge (Jensen and Vanni,
2002). The same ROIs were used for data recorded with DBS in the on
and off conditions. 
4.3.3 Power spectral density
Power spectral densities (PSD) of MEG, EMG and accelerometer signals
were estimated for each subject using Welch's method with 50%
overlapping 1024-point Hanning windows, which resulted in a frequency
resolution of approximately 1 Hz. The PSD in Study III was normalized
by dividing it with the average PSD between 3 and 48 Hz. The grand
averages were calculated by averaging these normalized PSDs over the
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patients. The average spectra for DBS on and off conditions were
compared for 6 – 13 Hz and 13 – 25 Hz bands.
The EMG signal was high-pass filtered above 0.5 Hz, rectified, and then
averaged with a 51-point moving average filter to analyze the stability of
EMG in Study III. The following equation was used (Lim et al., 2011):
Stability of EMG = 1-(SD(EMG
rectified and averaged
) / Mean (EMG
rectified and averaged
)) 
The stability was averaged across all epochs of EMG to obtain individual
EMG stability values. This was done separately for DBS on and off
conditions. 
4.3.4 Coherence analysis
Sensor level CMC was estimated between the EMG and MEG signals in
Study III. The coherences in Study IV were estimated between three
different signal types: MEG, EMG and accelerometer signals. For three
orthogonal accelerometer channels, we used a signal corresponding to the
greatest singular value based on the singular value decomposition
4.3.4.1 Sensor-level coherence
The sensor-level coherence was estimated between the EMG or
accelerometer signal and signals from each MEG gradiometer pair in turn.
Welch's method with 50% overlapping 1024-point Hanning windows
(frequency resolution about 1 Hz) was applied. The number of averaged
segments used for coherence calculations varied (range 106 – 618; mean
in Study III 451 ± 118 and in Study IV 556 ± 54). The time segments in
Study IV were same for EMG and accelerometer data.
The location of the CMC / CKC maximum peak was established by visual
inspection from 15 selected gradiometer pairs for the sensorimotor cortex
contralateral to the activated hand. Peak strengths and frequencies were
determined from this maximum peak.
The coherence spectra in Study III were divided into 4 – 6 Hz, 6 –13 Hz
and 13 – 25 Hz frequency bands. A more detailed examination of the
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patients with CMC in the 13 – 25 Hz band was carried out by dividing the
patients into three groups. One group had significant CMC both in DBS
on and off conditions; one group did not have any CMC in either
condition, and one group had significant CMC when the DBS was either
on or off.
4.3.4.2 Source-space coherence
The MRILab software (Elekta Oy) was used to co-register MEG with an
anatomical MR image, aligning co-ordinates of the head and the MRI.
The FreeSurfer software (MGH, Boston, MA) or Seglab software (Elekta
Oy) was used for MR image segmentation. The segmentation separates
the brain from the surrounding tissue, thus providing a volume for
possible sources.
The Dynamic Imaging of Coherence Sources (DICS) method in
Beamformer software (Elekta Oy) was used for source-space coherence
estimation in Study IV. The sensor-level CMC and CKC peaks were used
as the basis for selecting 6-Hz frequency bands for coherence estimation,
and all further analyses were restricted to this band. An evenly distributed
grid of locations that covered the brain volume with a resolution of 3 mm
was used. Only the direction that had maximum power was used for each
location. A virtual electrode signal (estimate of source activity in the time
domain) was estimated from the location of maximum coherence after the
beamformer coherence scanning. The final CMC and CKC results were
computed using these virtual electrode signals.
4.3.5 Statistical analyses
SPSS (SPSS for Windows version 13.0 or 17.0, SPSS, Chicago, IL) was
used for statistical analyses. The results are reported as means ± standard
deviations when appropriate. The level of statistical significance was set
for p-value below 0.05.
Time-shifted coherence (coherence calculated by shifting EMG data 3
seconds in relation to the MEG data) was used for testing the statistical
significance of the sensor-level coherence. Any true coherence in these
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data was presumably destroyed by the shift. The significance level was
set at 99% of the time-shifted coherence (Salenius et al., 2002).
Comparisons of the DBS on and off states data within individuals in
Study I were made using the paired t test. The statistical comparisons in
Studies II, III and IV between two dependent groups were analyzed by
Wilcoxon Signed Ranks Test. The comparisons between three different
groups in Study III were analyzed by the Kruskal-Wallis test and Dunn's
multiple comparison tests. The Mann-Whitney test was used for
comparison of the distributions of two independent groups (Study III).
Spearman correlation was used in Studies II, III and IV to calculate the
significance of correlations.
The x-axis co-ordinates in Study IV were transformed to positive values
(absolute values of the x-co-ordinates) for statistical calculations and a
one-sample t-test was used for the calculations of significance for co-
ordinate differences.
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5 RESULTS AND DISCUSSION
5.1 Feasibility of MEG in studies of the effects of DBS (Studies I
– III)
Carrying out studies of the effects of DBS on brain electrophysiology is
challenging. Devices that are used for DBS are magnetic; patients that
have DBS battery implants cannot be studied with functional MRI, and
transcranial magnetic stimulation (TMS) of these patients can be
hazardous. DBS, on the other hand, does not complicate PET or single
photon emission computed tomography (SPECT) studies. PET and
SPECT, however, produce only indirect measures of neural activity as
they explore the changes in blood flow or metabolism. Moreover, their
temporal resolution is not good enough to study brain oscillations.
Repeated PET or SPECT measurements may also expose the patient to
the effects of excessive radiation.
EEG and MEG are non-invasive methods with high temporal resolutions.
DBS can cause huge electrical /magnetic artifacts that may mask all
measurable brain signals. This confounding property has hindered both
the use of EEG and MEG in this field. The tSSS method, fortunately,
provides robust artifact suppression for MEG data and we wanted to study
its usefulness with DBS studies.
The artifact suppression used In Study I was accurate enough to enable
evoked field studies. The patients had the connecting wires and the
battery placed on the left side, which resulted in stronger artifacts over the
left hemisphere; consequently, signal-to-noise ratio was better in the right
than left hemisphere. Adequate contralateral N100m responses were
found from 10/12 right and from 8/12 left hemispheres. The P60m SEF
responses were detected from 11/12 right and 10/12 left hemispheres. The
N20m SEFs were found only in 3/12 of the left and 9/12 of the right
hemispheres. Both AEFs and SEFs corresponded in form, timing and
location to those reported previously for healthy subjects. The variance of
the results may have been increased by any artifacts that remained in the
data even after tSSS. Indeed, if the recording amplifiers were saturated by
the DBS artifacts during the measurement, no brain data would be
captured and artifact suppression methods could not restore those data.
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Figure 5. The amplitude spectra of spontaneous brain activity. The band in the right-side
(B and D) image shows spectra for the 0 – 300 Hz frequency range, upper figure (A and
B) shows DBS on, and lower figure (C and D) shows DBS off. On the left side (A and
C) spectra from one sensor triplet in the 0 – 40 Hz band. The green line is the spectrum
without tSSS, the dashed blue line shows the spectrum after tSSS with correlation limit
of 0.9 and black line after tSSS with correlation limit of 0.8. The artifact peaks produced
by the DBS are clear when the DBS was on. The peaks appear symmetrically around the
stimulation frequency of 130 Hz. A: tSSS does not totally remove the DBS artifact peaks
at 20.7 Hz (black arrowhead) or 32.4 Hz (open arrowhead). D: When DBS is off, the
mains 50 Hz artifact and its harmonics can be detected. C: tSSS adequately suppresses
the low frequency artifacts that are also present when DBS is off. They arise from the
wires and battery when they are moved e.g., by movement of the chest due to respiration.
Modified from Study II.  
Spontaneous data analysis was fraught with more problems. The tSSS
method effectively suppressed most DBS artifacts, but some narrow
interference peaks were left in the spectra, particularly when the DBS was
on (Figure 5). One of these artificial peaks was found at 130 Hz, at the
rate of DBS. Additional artifact peaks spread symmetrically above and
below the stimulation frequency. The lowest artifact peaks were found at
20.7 Hz and 32.4 Hz but were not totally erased by tSSS. Artifacts were
more robust in the left than right hemisphere, above the wires that
connected the DBS battery to the electrodes. Monopolar stimulation
produced stronger artifacts than the bipolar stimulation. The DBS
probably produces some high-frequency interference that is not
sufficiently suppressed by the applied anti-aliasing filters of the used
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MEG device. An aliased DBS-interference component, however, did not
completely explain the artificial spectral peaks in our phantom
experiments (see 6. Additional Material).
5.2 DBS effects of evoked fields (Study I)
The AEF N100m response to right-ear stimulation was significantly
enhanced in the right hemisphere (49 ± 17 nAm DBS on, 43 ± 16 nAm
DBS off: p < 0.05). The contralateral N100m mean source strengths
increased non-significantly when DBS was on (left hemisphere: 47 ± 22
nAm DBS on, 44 ± 19 nAm DBS off and right hemisphere: 61 ± 26 nAm
DBS on, 58 ± 22 nAm DBS off) (see Figures 6 and 7).
The SEF source strengths were non-significantly increased when DBS
was on. The AEF and SEF response latencies were not modified by DBS. 
5.2.1 Discussion of Study I
The AEF N100m amplitude at the group level increased significantly in
the right hemisphere for ipsilateral stimulation. The worse data quality
was found in the left hemisphere. This was probably due to left-sided
electrode leads in most patients. Hence DBS artifacts may have masked
the effect in the left hemisphere. The ipsilateral auditory pathways from
the inner ear to the cortex through the thalamus are thinner than
contralateral ones. The ipsilateral auditory pathways are thus possibly
more sensitive to DBS effects than the contralateral pathways. We did not
find an effect of DBS on latencies of N100m as reported in auditory
event-related potentials elicited by an oddball paradigm (Naskar et al.,
2010). Naskar and collagues applied auditory stimuli bilaterally;
consequently, ipsilateral and contralateral responses were not examined in
their study. The alpha-band coherence between STN and superior
temporal gyrus (including the auditory cortex) has confirmed a
connection between the two areas (Hirschmann et al., 2011; Litvak et al.,
2011).
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Figure 6. AEFs of one patient before (A) and after (B) tSSS. The responses are shown
from above, with the patient's nose pointing upwards. The black line shows DBS on and
the red line shows DBS off. The stimulus was delivered to the right ear, inducing the
strongest responses in the left hemisphere. AEFs in the squares are shown in Figure 7.
Modified from Study I.
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Figure 7. AEFs of one patient selected from the whole-head data in Figure 6 and shown
in enlarged form. The upper box depicts data before and the lower box after the tSSS.
The black line shows DBS on, red dotted line shows DBS off. The strongest deflection
peaks at 100 ms (N100m). Modified from Study I.
No significant differences were found in the SEFs between DBS on and
off conditions. The previously reported effects of DBS on somatosensory
evoked potentials were not totally uniform (Pierantozzi et al., 1999; Priori
et al., 2001). In our study considerable inter- and intraindividual variation
of the DBS effects and also the antiparkinsonian medication during the
measurements might have influenced the results. 
The effects of DBS on SEFs and AEFs were modest but the observed
changes suggest that STN-DBS modifies the thalamocortical pathways
and / or cortical processing. The effect of DBS on late evoked potentials
also supports the notion that a proportion of the DBS effects take place at
the cortical level.
5.3 DBS effects on spontaneous brain rhythms (Study II)
The effect of DBS on 10 and 20 Hz spontaneous cortical activity was very
variable. Depending on the individual, the signal strength could be
stronger or weaker when DBS was on vs. off. When DBS was turned on,
group level results of the source strengths of pericentral cortical regions
revealed a non-significant decrease in the 6 – 10 Hz band, around the
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individual mu rhythm peak in the 5 – 11 Hz range, and in the lower and
higher beta ranges (Figure 8).
Figure 8. Sources of spontaneous 12 – 20 Hz brain activity with eyes closed for both the
DBS on and off conditions. The frequency domain Minimum Current Estimates
averaged over four patients with 20-Hz activity increased in the pericentral region when
DBS was off. The ROIs were formed individually for each patient using the area that is
marked with the rectangle on the left. Modified from Study II.
 
The peak frequencies of occipital alpha rhythm varied between 5.7 Hz
and 10.9 Hz. When eyes were closed and DBS was turned on the source
strengths around the individual peaks (± 2 Hz) decreased from 7.6 nAm to
7.1 nAm (p = 0.05). When the patients' eyes were open the source
strengths decreased from 6.2 to 5.7 (p = 0.33). 
5.3.1 Correlation of the spontaneous brain rhythms with the motor
state
The source strengths of the 6 – 10 Hz and 12 – 20 Hz signals and the
source strength of the peak frequency in the 5 – 11 Hz band in the
pericentral region correlated with coefficients from a minimum of 0.65 (p
= 0.03) with UPDRS rigidity subscores when the patients' eyes were open
and DBS was on (Table 2, Figure 9). 
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Correlations between UPDRS action tremor scores and pericentral 6 – 10
Hz and 21 –30 Hz source strengths and the source strength of peak
frequency in the 5 – 11 Hz band were seen, when DBS was off (Table 2,
Figure 9). These correlations were particularly marked when the eyes
were open. 
Table 2. Spearman correlations between the pericentral signal source strengths and
UPDRS rigidity or action tremor subscores when the patients' eyes were open.
Frequency band UPDRS rigidity 
(DBS on)
UPDRS action tremor 
(DBS off)
Spearman's rho
6 – 10 Hz 0.0687 (p = 0.019) 0.645 (p = 0.032)
12 – 20 Hz 0.0668 (p = 0.025) 0.565 (p = 0.070)
21 – 30 Hz 0.510 (p = 0.109) 0.782 (p = 0.004)
5 – 11 Hz peak 0.748 (p = 0.008) 0.673 (p = 0.023)
The individual peak frequency in the 5 – 11 Hz band in the pericentral
region correlated negatively with rigidity subscores when eyes were
closed and DBS was off (r
s
 = -0.735, p = 0.01). 
Occipital alpha activity source strength correlated significantly with
UPDRS action tremor scores when DBS was off particularly when eyes
were open (rs = 0.848, p = 0.001) (Figure 9).
The peak frequency of occipital alpha had negative, significant
correlation with UPDRS total motor scores (DBS on: rs = -0.621, p =
0.041, DBS off: rs =  -0.689, p = 0.019) and rigidity subscores (DBS on: rs
=  -0.646, p = 0.032, DBS off: rs = -0.711, p = 0.014) when the eyes were
closed. 
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Figure 9. Scatterplots of UPDRS rigidity (A, B) and action tremor (C, D) scores and
source strengths of spontaneous brain activity with eyes open from parietal ROI at peak
(±2 Hz) frequency in the 5 – 11 Hz range (A), and in the 12 – 20 Hz range (B) and from
occipital ROI at alpha (C) and from parietal ROI in the 21 – 30 Hz range (D). A and B:
DBS on (black line); C and D: DBS off (grey line). Modified from Study II. 
5.3.2 Discussion of Study II
The DBS effect on spontaneous MEG of individual patients varied
considerably. DBS decreased the oscillatory beta activity over the
sensorimotor cortex on the group level but this effect was non-significant.
Increase of beta band activity elicited by DBS over the whole cortex has
been reported (Cao, 2015). Several reasons may explain this difference
between the two studies. Patients that were studied by Cao were recorded
without simultaneous medication and they had already received a longer
DBS treatment at the time of the MEG measurements. Moreover, only
sensor space data from magnetometers were reported in Cao's study. In
both studies some frequencies had to be omitted from the analysis
because of artifact peaks.
53
The DBS effect on cortical beta activity may well be more complex than
uniform modulation of its strength. A study of cortical phase-amplitude
coupling of electrocorticography (EcoG) recorded from the motor cortex
of PD patients going through DBS implantation, before, during and after
STN stimulation, found both increases and decreases in cortical beta
power due to DBS (de Hemptinne et al., 2015). The authors noted,
however, that all patients had a significant decrease of phase-amplitude
coupling between cortical beta band and broadband signals during DBS.
They also noted a difference between the effect of DBS on beta power in
the cortex and the STN; DBS decreased more often the STN beta power
than cortical beta power. 
In MEG recording with DBS on the mu rhythm amplitude correlated
significantly with the UPDRS rigidity scores. Consequently, mu rhythm
modifications by DBS seem to be related to the therapeutic effect of DBS.
DBS may also reduce pathological, rigidity-related oscillations or “noise”
in the spontaneous activity in the sensorimotor system. When DBS was
off, however, the source strengths of beta band activity did not correlate
with UPDRS rigidity subscores. It has also been reported that total power
of the signal recorded by the STN electrodes in the 13 – 35 Hz range did
not correlate with the clinical state at rest without treatment (Chen et al.,
2010).
The 6 – 10 Hz signal from both the pericentral and occipital areas
correlated with the action tremor when DBS was off. Although the
patients were resting during the measurements, a slight action tremor in
the 7 – 12 Hz range could not be excluded.
 
In PD patients without DBS, the EEG and MEG resting state oscillatory
activities slow down (Soikkeli et al., 1991; Bosboom et al., 2006). The
average peak frequency of the spontaneous oscillatory activity across the
whole cortex has also been shown to be lower when stimulation was off
than when it was on (Cao, 2015). In our study DBS did not modify the
peak frequencies of the oscillatory activity. Nevertheless, the occipital
alpha peak frequency correlated negatively with total UPDRS motor and
rigidity subscores, which indicated that the motor condition was worse
when occipital alpha frequency was lower.
The number of patients in this study was quite small for calculating
correlations and correlation does not necessarily imply causality.
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5.4 The effects of DBS on CMC (Study III)
Significant coherence peaks were detected in the 13 – 25 Hz range in 15
out of 19 patients. The mean frequency was 17.7 (± 3.2) Hz when DBS
was on and 18.1 (± 3.1) Hz when DBS was off. 11 patients had
statistically significant CMC for both DBS on and off conditions. Two
patients had a significant coherence only when DBS was on and two
patients had CMC only when DBS off (Figure 10).
Figure 10. A: Cortico-muscular coherence spectra of one patient from 102 gradiometer
pairs. The sensors are viewed from above, and the patient's nose points upwards. The
maximum CMC peaks over the sensorimotor cortex contralateral to the activated hand.
B-D: CMC from one sensor over contralateral sensorimotor cortex from one patient
showing a decrease in CMC when the DBS was on (B), one patient showing an increase
in CMC when the DBS was on (C) and one patient without CMC (D). The black line
depicts DBS on, the red line shows DBS off. Dotted horizontal lines indicate the 99%-
significance level. Modified from Study III.
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Eight patients had a significant CMC both when DBS was on and off in
the 6 – 13 Hz range; the mean frequency was 10.8 (± 2.0) DBS on and
11.1 (± 1.9) when DBS off. Moreover, three patients had CMC only when
DBS was on and three patients only when DBS was off in this frequency
range, and four patients did not manifest CMC when DBS was either on
or off. CMC in the 4 – 6 Hz range was found only in five patients. The
CMC peak frequencies or strengths did not differ significantly between
DBS on and off. 
5.4.1 Correlation of CMC with the motor state
     
The CMC peak amplitude in the 13 – 25 Hz range correlated negatively
with tremor scores when DBS was off (rs = -0.561, n = 13, p = 0.046,
two-tailed); when tremor scores were high the CMC peak amplitudes
were small. In the 6 – 13 Hz range the CMC peak amplitudes correlated
negatively with the tremor scores of the activated hand when DBS was
off (rs = -0.616, n = 12, p = 0.033, two-tailed). 
When DBS was on, the CMC amplitude in the 13 – 25 Hz range
correlated negatively with the tremor of the activated arm (rs = -0.756, n =
10, p = 0.011, two-tailed) and total tremor scores (rs = -0.795, n = 10, p =
0.006, two-tailed). The CMC peak frequency and the tremor scores of the
activated hand correlated negatively when DBS on (rs = -0.654, n = 10, p
= 0.040, two-tailed) in the 6 – 13 Hz band.
In the patients whom UPDRS scores were decreased more than 30% by
DBS, correlations between CMC parameters and tremor scores were
present as well. Peak frequency in the 6 – 13 Hz band correlated
negatively with total tremor scores when DBS was on (rs = -0.836, n = 6,
p = 0.038, two-tailed). Moreover, CMC peak amplitude and the rigidity
scores of the activated hand correlated negatively when the DBS was on
in the 13 – 25 Hz band (rs = -0.769, n = 8, p = 0.026, two-tailed) in this
group. 
5.4.2 CMC correlation with clinical conditions of patients
The CMC peak amplitude in the 6 – 13 Hz band correlated with age of the
patients when DBS was off (rs = 0.599, n = 12, p = 0.040, two-tailed). In
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patients for whom the DBS decreased the UPDRS scores by more than
30%, age correlated with the peak frequency when DBS was off (rs =
0.845, n = 6, p = 0.034, two-tailed) and with the peak amplitude when
DBS was on (rs = 0.812, n = 6, p = 0.05, two-tailed).
5.4.3 Differences between subgroups based on the presence of CMC 
in the 13 – 25 Hz band
The patients were divided into three subgroups with different CMC
appearance: One group had no CMC for the DBS on or off conditions
(CMC- subgroup), another group had CMC in only DBS on or off
(CMC± subgroup) and CMC+ subgroup had CMC both DBS on and off.
All patients that had CMC in the 13 – 25 Hz band for DBS on and off
conditions (CMC+ subgroup) had a rigid-akinetic type of PD. DBS
voltages differed between the groups: the largest stimulation voltages
were given to the CMC+ subgroup (p = 0.05). The patients in the CMC±
subgroup managed with the lowest LEDD (p = 0.015). There was no
difference in the preoperative LEDD between the subgroups. The mean
time between the DBS operation and the MEG measurement differed
between the groups (p = 0.013). The age or disease duration did not differ
significantly between these subgroups. The total UPDRS motor scores
between these subgroups were statistically different (DBS on p = 0.028;
DBS off: p = 0.020). The best UPDRS scores were obtained from the
CMC+ subgroup both for DBS on and off conditions. (Table 3)
Table 3. Clinical parameters in different subgroups based on the presence of CMC in the
13 – 25 Hz band. CMC+ = CMC both DBS on and off, CMC- = no CMC for DBS on or
off, CMC± = CMC DBS on or off, LEDD = levodopa equivalent daily dose
CMC+ CMC- CMC±
DBS voltages 3.5 ± 0.9 V 2.7 ± 0.6 V 2.6 ±0.3 V
LEDD 1070 ± 420 mg 1410 ± 655mg 440 ± 160 mg
Time between DBS 
operation and MEG 
measurement
10 ± 7.3 
months
23 ± 3.9 
months
5.5 ± 0.9 
months
Total UPDRS, DBS on 16.5 ± 6.0 31.3 ± 6.7 24.5 ± 15.6
Total UPDRS, DBS off 28.2 ± 12.9 39.3 ± 9.1 55.8 ± 16.7
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5.4.4 Discussion of Study III
CMC was found in this patient group as frequently as that reported for
healthy subjects (e.g. (Pohja et al., 2005; Bourguignon et al., 2013)). The
DBS effect on CMC varied between individuals. We did not find
systematic increases in CMC in the 13 – 25 Hz range, contrary to our
anticipated increase of CMC with DBS, based on a previous PD study
reporting an increase in CMC by levodopa (Salenius et al., 2002). The
functional role of CMC even in healthy subjects is not yet fully
understood. CMC may be missing in people with totally normal ability to
move and training has shown to have conflicting effects on it (Ushiyama
et al., 2010; Mendez-Balbuena et al., 2012). 
CMC in patients with an early stage PD did not differ from age-matched
controls (Pollok et al., 2012); thus a weak CMC is probably not a
hallmark of PD. The effect of levodopa on CMC also varies between
patients (Salenius et al., 2002). Enhancement of CMC activity by
levodopa was also not detected in recordings one day after DBS electrode
implantation (Hirschmann et al., 2013). 
It is also possible that STN stimulation suppresses cortical activity in such
a small area close to the hyperdirect pathway (Whitmer et al., 2012) that
CMC is not influenced by such focal changes. STN-DBS may also
modulate the motor function by altering the descending outputs from the
basal ganglia, e.g., via the brainstem motor control centers (Delwaide et
al., 2000).
The negative correlation of CMC in the 13 – 25 band with UPDRS tremor
subscores may demonstrate the well-known suppression of the CMC by
movements (such as tremor) in this frequency range. An increase in CMC
with DBS treatment was reported to correlate with decreased tremor in
three patients (Park et al., 2009).  
Some features of our data, however, indicate the beneficial effect of CMC
in the 13 – 25 Hz band. The best UPDRS scores were seen in patients
who manifested CMC in this frequency band for DBS in both on and off
conditions. Moreover, the patients with no CMC over this range needed
the most medication. 
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CMC may reflect both the functional properties of muscle co-ordination
and some pathophysiological features of PD such as rigidity. Transcranial
alternating current stimulation (tACS) at 20 Hz increased beta CMC and
slowed down movements in healthy control subjects (Pogosyan et al.,
2009), whereas in PD patients it attenuated CMC and made the amplitude
of finger tapping more regular (Krause et al., 2014). We were not able to
separate the functional and pathological features of CMC.
CMC peak amplitude and frequency both correlated negatively with
UPDRS tremor scores in the 6 – 13 Hz range. The importance of this
finding remains uncertain because several patients had zero tremor scores.
5.5 CMC and CKC in 10 healthy volunteers (Study IV)
Significant CMC was detected in 19 out of 20 hemispheres, and
significant CKC was found in 20 hemispheres of 10 healthy subjects.
Data from 19 hemispheres with both CMC and CKC were analyzed. The
frequency distributions of the CMC and CKC peaks overlapped at least in
part in 15 hemispheres. The similarities of the CKC and CMC values in
both hemispheres enabled their pooling across the hemispheres. The
intraindividual variability between the right and left hemispheres within a
subject was less prominent than the noticeable variability seen when
CMC and CKC were compared between individuals. 
The mean peak CMC frequency was 23 Hz and CKC mean peak
frequency 21 Hz (p = 0.013). The mean peak frequencies of CMC and
CKC correlated (r
s
 = 0.681, n = 19, p = 0.001, two tailed). The mean
maximum CMC amplitude was 0.1 ± 0.05 and the mean maximum CKC
amplitude was 0.08 ± 0.04 (p = 0.059). Maximum CMC and maximum
CKC amplitudes correlated significantly (r
s
 = 0.575, n = 19, p = 0.010,
two tailed). The source location co-ordinates did not differ significantly
between CMC and CKC within different hemispheres (Figure 11).
The peak frequency of accelerometer power spectrum between 6 – 14 Hz,
considered to contain the tremor frequency, did not correlate with CMC
(r
s
 = -0.178, n = 19, p = 0.465, two tailed) or CKC (r
s
 = 0.045, N = 19, p =
0.854, two tailed) peak frequencies.
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Figure 11. Source localization of CMC (left) and CKC (right) in one subject. Modified
from Study IV.
5.5.1 Discussion of Study IV
CMC and CKC spectra in most subjects resemble each other and the
beamformer source locations of simultaneously recorded CMC and CKC
were nearly identical. The task was to extend the wrist and hold the hand
still, thus the accelerometer signals (and CKC) were generated by postural
tremor. The accelerometer power spectra revealed a low-frequency peak
between 5 and 11 Hz in nine out of ten patients. This peak probably has it
origins in the small-amplitude postural tremor. Hence, we suggest that the
physiological mechanisms related to postural tremor are registered in
CMC. A previous study of PD patients revealed an elevated CMC in the
12 – 18 Hz band in patients with strong postural tremor (Caviness et al.,
2006) supporting this notion.
Small differences between CMC and CKC spectra are not surprising even
when they reflect the same phenomenon, because the EMG electrode
records signals from one muscle but the postural tremor probably relates
to activity of several muscles. 
The accelerometer signals are also useful in CKC estimates in the
stationary hand position used in this study. The accelerometer is often
easier to use than EMG as EMG electrode placement is more vulnerable
and when the EMG electrode is attached on the skin the skin may move
relative to the examined muscle.
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6. ADDITIONAL MATERIAL  
6.1 Motivation
The motivation for this additional previously unpublished material came
from the numerous sharp peaks found in the spectra of spontaneous brain
activity during DBS treatment (Study II, Figure 5). The peak frequencies
were so regular in the patients that their biological origin was doubtful.
Nevertheless, the patients were stimulated by regular pulse frequencies;
therefore it could have been possible that this exogenous rhythm paced
the neurons in a very regular way. 
6.2 Methods
We explored this phenomenon in more detail by measuring the pure DBS
signal without the ‘disturbing’ neural activity and by taking the
measurements in such a way as to test several different stimulator
parameters without concerns. Watermelons turned out to be suitable
‘phantom brains’.
We implanted Kinetra and Activa PC Neurostimulators into watermelons.
The melon measurements were carried out at the BioMag Laboratory and
a t MEG Core of the Brain Research Unit, Aalto University. The MEG
centers at Aalto University and the Helsinki University have Elekta
Vectorview™ MEG devices but their software are slightly different. The
MEG at Aalto University enables recordings with higher sampling rates.
One-minute recordings were collected for different DBS and MEG
parameters (Figure 12). The spectra were calculated with Graph software
(Elekta Oy) with 50% overlapping 1024-point Hanning windows. No
statistical comparisons were done.  
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Figure 12. DBS programming between watermelon recordings
6.4. Results
Similar spectral peaks as found in patient data (Study II) were detected in
the watermelon measurements during DBS. This indicates that their
generation did not require a neural substrate, and they were consequently
stimulation artifacts. 
tSSS method was also efficient at suppressing DBS artifacts from these
data (Figure 13 A). The spectral peak frequencies were slightly different
between Kinetra and Activa PC DBS devices (Figure 13 B). Different
MEG settings (band pass, sampling frequency) modified the peak
frequencies (Figure 13 C). As the higher sampling frequency generated
artifacts at the lower frequencies than lower sampling frequencies, the
artifacts are not totally explained by an aliased DBS-interference
component. 
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Figure 1 3 . The amplitude spectra of DBS-induced spectral peaks in a watermelon
measured in the BioMag laboratory. The frequency range is 0 – 300 Hz. 
A: The amplitude spectra before (black) and after (red) tSSS. Artifact peaks similar to
those found in patient measurements were detected (peak at 20.9 Hz marked with “v”
and at 33.9 Hz with “*”). B: Comparison between Kinetra (black) and Activa PC (red)
devices. Small differences were observed in amplitudes and frequencies of spectral
peaks. C: The used band pass and sampling frequency had an effect on artifact peaks.
The black line represents the usual settings (bandpass 0.03 – 330 Hz, sampling
frequency 1011 Hz). When the high pass filter was set at 100 Hz the artifact peaks
decreased but did not totally vanish (red). Higher sampling rate at 2018 Hz (turquoise)
increased the peaks and changed their frequencies.
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6.5 Discussion of additional material
These DBS measurements with watermelons confirmed that the sharp
spectral peaks seen in our patient data are mostly artifacts. This finding
does not rule out that some neural activity could be driven by the DBS
stimulation frequency (see e.g. Walker et al., 2012). The experiments in
Study IV also verified that the MEG recording parameters also have an
effect on the appearance of the artifactual frequency peaks, which
highlights the importance of parameter optimization. The artifact patterns
also differed between the two MEG devices (not shown) so that the
artifact problems of different MEG centers may not be identical.
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7. GENERAL DISCUSSION
The effects of STN-DBS on the brain's electrical activity were studied in
advanced PD patients treated with DBS. The measurements included
recordings of evoked potentials, spontaneous brain activity and CMC. All
were measured when DBS was both on and off. One study (IV) was done
with healthy volunteers to examine the effect of postural tremor on CMC
to gain a better understanding of the properties of CMC. 
The tSSS method suppressed the DBS-induced magnetic artifacts quite
well. Nevertheless all artifacts were not totally erased. Therefore the data
must be examined carefully even after using artifact suppression with
tSSS. Reducing the correlation limit of tSSS enhanced the clearance of
the data but at some point the brain signals may be affected as well. The
correlation limit of 0.8 has been shown to be fairly safe (Medvedovsky et
al., 2009). The artifact problems, related to the placement of the DBS
wires and battery and filter settings, should be taken into account during
the study design. The frequencies used by head indicator coils and the
sampling rates that are optimal for DBS recordings should both be
selected carefully. 
These studies focused on signals at and below the beta range. We
observed that the DBS-related artifacts centered on frequencies above this
range. The artifacts of DBS may be particularly hard to cope with when
exploring signals in higher frequency bands. For example, DBS may also
induce brain activity in the gamma band frequencies (Garcia et al., 2005).
Oscillations at about 300-Hz have been shown to be of interest in PD
because LFP recordings of STN have indicated 300-Hz rhythm that is
dopamine- and movement-dependent (Foffani et al., 2003). At present,
oscillations at 300-Hz frequency range are not easily studied by MEG in
patients with DBS on.  
The effects of DBS on cortical activity were studied in this thesis. The
results were somewhat inconsistent. We did not find a simple parameter
that exclusively reflected the effect of STN-DBS in advanced PD.
Although several studies emphasize the importance of cortical activity in
directing STN activity in animals (Gradinaru et al., 2009) and in patients
(Marsden et al., 2001; Fogelson et al., 2006; Litvak et al., 2011), some
effects of DBS may be mediated via deeper brain structures that are not
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directly visualized in MEG signals (Delwaide et al., 2000). It may also be
the case that the DBS-induced effects are better highlighted in more
complex aspects of cortical electrophysiology, not analyzed by us, e.g. in
reduced cortical phase-amplitude relationships (de Hemptinne et al.,
2015).
The patients could have had occasional tremor periods during the
recordings, which might have affected the spectra of spontaneous brain
activity (Mäkelä et al., 1993) or CMC. A slight tremor may affect the
CMC results by generating a CMC at the tremor frequency and its
harmonics (Volkmann et al., 1996; Timmermann et al., 2003). A strong
tremor might even induce widespread fluctuations of the measured
magnetic fields. If CMC is affected by postural tremor as we speculate,
t h e n t h e monitoring the tremor during the measurement with
accelerometer would be relevant.
Antiparkinsonian medication could also produce some variability in our
results. The patients continued their medication during the recordings to
make the measurement easier for them. Therefore, we reported combined
effects of DBS and antiparkinsonian medication. This may have had an
influence on the results. A saturation effect was not probable in our
studies as the DBS improved the motor state of the patients. Although
medication was administered during the measurements, the fluctuations in
the medication levels could not be totally controlled. 
The stun effect, improvement of the symptoms by the micro-lesion caused
by electrode insertion, should not have been problem in our studies as it
has reported to vanish within one month after insertion of the electrodes
(Jech et al., 2012). We did not have a precise delineation of the electrode
locations in the STN at our disposal. However, the DBS was efficient in
all our patients. This indicated that the DBS target was adequate.
The CMC has traditionally been estimated between EMG and brain
signals. However, EMG has many limitations. Even the exact EMG-
electrode placement may be difficult if the skin moves in relation to the
underlying muscles during or between the recordings. The usefulness of
EMG rectification has also been debated lately. Previously it has been
regularly used in CMC calculations. Rectification of EMG was thought to
enhance firing rate information and thus be a necessary pre-processing
step for CMC analysis (Myers et al., 2003). The EMG was rectified in
Study III. Recent literature has argued against the rectification of EMG
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(Neto and Christou, 2010; McClelland et al., 2012). Therefore the EMG
rectification was omitted in Study IV. The rectification has been reported
to have erratic effects on the coherence spectra and even obscure the
CMC detection in some cases (McClelland et al., 2012), thus it may have
affected our results in Study III unfavourably. The problems regarding
EMG in such studies make alternative approaches interesting and data in
Study IV indicates that an accelerometer may also be used for coherence
estimations during stationary hand positions, and not only during the
movements.
At least three hours of STN-DBS off is required to establish a steady DBS
off state for efficacy studies (Temperli et al., 2003). However, about 50%
of the total change has been estimated to occur in as little as 5 minutes
after DBS is turned off (Little et al., 2013). In all but one of our patients
the MEG measurements were done first with DBS on and then DBS off.
The DBS switching was done in a shielded room but the patient, seated in
the measurement chair, was taken out from the helmet to get some
distance between the MEG sensors and programmer device. There was an
interval of several minutes before measurements were resumed. The
actual time of switching off DBS before the DBS off measurements was
not recorded. Most often the DBS off measurements were started with
evoked field recordings, which thus had the least time to be affected by
turning DBS off. The difference in results between DBS on and off states
could have been clearer if the time between switching off the DBS and
starting the measurement had been longer. 
There are only a few previous MEG studies of chronically DBS treated
PD patients, and those studies used small groups of patients. We, by
comparison, studied a relatively large number of patients. Nevertheless,
the patient numbers are still small, particularly for subgroup analyses, and
this needs to be taken into account when interpreting the statistical results.
In the future, DBS that is adaptive to the clinical condition of individual
patients may produce better efficacy and longer duration of the implanted
battery than the present stimulation strategies. Studies of adaptive DBS in
Parkinsonian non-human primates (Rosin et al., 2011) and in patients
(Little et al., 2013) have suggested a potentially better efficacy in
ameliorating PD symptoms than conventional DBS. The adaptability can
be obtained by monitoring the electrophysiological changes of the patient.
MEG may provide clues for the appropriate neuromodulatory effects of
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DBS on long-range brain networks of PD patients, which would be a
prerequisite for an optimal clinical outcome.
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8. SUMMARY
MEG studies of DBS patients are challenging. DBS may preclude MEG
measurements totally as artifacts produced by DBS conceal brain signals
in the recorded data. The studies presented and summarised in this thesis
show that the MEG data recorded in DBS-treated PD patients is amenable
to analyses in the vast majority of the cases after artifact rejection by
tSSS. Studies of previously well known SEFs and AEFs demonstrate that
DBS artifacts can be removed efficiently and that the remaining signals
contain physiologically valid data (Study I).
The precise mechanisms of action of the DBS treatment are still unclear.
Thus we studied the alterations in the electrical activity of the brain
caused by DBS. The auditory and somatosensory evoked fields in Study I
revealed an AEF N100m amplitude increase in the right hemisphere for
ipsilateral sound stimuli when the DBS was on. This indicated that
cortical activity is modified by DBS.
 
The effects of DBS on spontaneous brain activity and CMC were not
uniform between patients. Nonetheless, some correlations to clinical
parameters were found. Patients with a clear suppression of beta range
source strength of sensorimotor spontaneous activity also had the clearest
reduction in rigidity (Study II). Levodopa has been reported to enhance
CMC in some studies, but we did not find a similar systematic increase in
CMC in the 13 – 25 Hz band during DBS in Study III. In contrast, CMC
decreased in the majority of the patients during DBS. However, the
absence of CMC was associated with higher doses of medication. This
suggested that CMC may partly reflect compensatory phenomena to
diminished dopamine demand (Study III).
CMC may reflect the interplay between cortical and muscle activities.
However, the functional role of CMC even in healthy subjects is not yet
fully understood. We studied simultaneous CMC and CKC of healthy
volunteers during a static hold task to enhance our knowledge of the
physiology of CMC. CMC and CKC were quite similar in healthy
volunteers. This suggests that CMC may relate to postural tremor, the
source of kinematics in the static muscle contraction task (Study IV). It
was possible to measure CKC during the static wrist extension in healthy
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subjects. Thus an accelerometer may prove to be useful for coherence
measurements in the future.
Data in this thesis show that MEG studies of DBS-treated PD patients are
feasible after applying tSSS for artifact suppression. DBS modifies
cortical electrical activity, and some of these modifications correlate with
the clinical improvement of PD patients. Moreover, the accelerometer
signals are useful in CKC estimates recorded during a stationary hand
position task. 
DBS is also used as an experimental therapy in several other disorders,
such as epilepsy, obsessive-compulsive disorders, dementia and chronic
pain, therefore the methods used in this thesis can be applied to study the
pathophysiology of these conditions as well.
70
ACKNOWLEDGEMENTS
This thesis project was carried out in the BioMag Laboratory and in the
Department of Neurology of Helsinki University Hospital. I want to
express my gratitude for BioMag Laboratory for providing research
facilities. Docent Markus Färkkilä and Docent Nina Forss the former and
present heads of the Department of Neurology and Professor Timo
Erkinjuntti are particularly thanked for providing an inspiring and
research-friendly working atmosphere. 
My heartfelt thanks go to my supervisors Docent Eero Pekkonen and
Docent Jyrki Mäkelä. Eero introduced me to DBS and taught me a lot
about Parkinson's disease. Without him the recruitment of the patients to
these studies would have been impossible. Jyrki led me to the world of
MEG. His wide experience has been crucial in meeting the challenges
during this project. I feel privileged to have had two so easily
approachable and dedicated supervisors.
I want thank Docent Valtteri Kaasinen and Professor Esa Mervaala for
carefully reviewing the manuscript and giving valuable comments. My
sincere thanks also go to Professor Karen Østergaard for accepting the
role of opponent.
I am deeply grateful for all my co-authors. Special thanks to Samu Taulu,
without tSSS this project would never have started, and Jussi Nurminen
and Jarkko Luoma who both patiently helped me with computers and
answered all my small and big questions related to physics and to MEG
analyses.
Without the great “BioMag people” this work might not have seen the
end. No matter how difficult the problems with this project were, you
were a good reason to come to the BioMag Laboratory. Thanks to all of
you, Ville, Andrey, Bei, Päivi, Juha M, Juha H, Juha W, Simo, Selja,
Pantelis, Ritva, Niko, Tuuli, Eini and others. 
Thank you also goes to Veikko Jousmäki for the accelerometer device
and Lauri Parkkonen for helping with the water-melon measurements in
Aalto University.
71
I want also thank Erik Johansen and Markus Butz for many interesting
discussions, also about MEG.  
My sincere thanks to my colleagues and friends in the Department of
Neurology in Meilahti. Especially my thanks to Docent Nina Forss and
Docent Seppo Kaakkola for being my follow-up group as well as Jukka
Lyytinen for helping me with the DBS tunings when needed. Kristina and
Eeva, you have been important peer supports, which I highly appreciate.
My warmest thanks to my colleagues in Peijas Hospital Pia, Marjo,
Marja, Krista and Chief of Neurology Department in Peijas Hospital
Elena Haapaniemi who has been flexible with timetables and gave her
support to this project. 
I am grateful to Pirjo Kari and Marja Bigler for helping me with all the
practical issues. Study nurses Suvi Heikkilä and Jari Kainulainen have
been great with the patients and patient with me, thanks for that.
I am thankful to the patients for participation and giving their time for the
sake of science. 
I give my most warm thanks to my parents Kirsti and Timo and my sister
Maria and her family for supporting and believing in me. 
Finally, I want to thank Mikko, you have been the most important motive
for me to finish this project. Thank you for diverting my attention outside
MEG and Parkinson's disease when needed.
This project was financially supported by the Academy of Finland (Grant
No. 122725) and by the SalWe Research Program for Mind and Body
(Tekes – the Finnish Funding Agency for Technology and Innovation
grant 1104/10). My work was also financially supported by the Finnish






Abelson JL, Curtis GC, Sagher O, Albucher RC, Harrigan M, Taylor
SF, Martis B, Giordani B. Deep brain stimulation for refractory 
obsessive-compulsive disorder. Biol Psychiatry 57: 510–516, 2005.
Albin RL, Young AB, Penney JB. The functional anatomy of basal 
ganglia disorders. Trends Neurosci 12: 366–375, 1989.
Alves G, Forsaa EB, Pedersen KF, Gjerstad MD, Larsen JP. 
Epidemiology of Parkinson’s disease. J Neurol 255: 18–32, 2008.
Baillet S. The Dowser in the Fields: Searching for MEG Sources. In: 
Hansen P, Kringelbach M, Salmelin R. MEG: An Introduction to 
Methods. Oxford University Press, 2010 p.83–123.
Benabid AL, Chabardes S, Mitrofanis J, Pollak P. Deep brain 
stimulation of the subthalamic nucleus for the treatment of Parkinson’s 
disease. Lancet Neurol 8: 67–81, 2009.
Benabid AL, Pollak P, Louveau A, Henry S, de Rougemont J. 
Combined (Thalamotomy and Stimulation) Stereotactic Surgery of the 
VIM Thalamic Nucleus for Bilateral Parkinson Disease. Stereotact Funct 
Neurosurg 50: 344–346, 1987.
Bosboom JLW, Stoffers D, Stam CJ, van Dijk BW, Verbunt J, 
Berendse HW, Wolters EC. Resting state oscillatory brain dynamics in 
Parkinson’s disease: An MEG study. Clin Neurophysiol 117: 2521–2531, 
2006.
Bourguignon M, Jousmäki V, Marty B, Wens V, Op de Beeck M, Van
Bogaert P, Nouali M, Metens T, Lubicz B, Lefranc F, Bruneau M, De 
Witte O, Goldman S, De Tiège X. Comprehensive functional mapping 
scheme for non-invasive primary sensorimotor cortex mapping. Brain 
Topogr 26: 511–523, 2013.
Bourguignon M, De Tiège X, de Beeck MO, Pirotte B, Van Bogaert P,
Goldman S, Hari R, Jousmäki V. Functional motor-cortex mapping 
using corticokinematic coherence. NeuroImage 55: 1475–1479, 2011.
73
Boyle A, Ondo W. Role of Apomorphine in the Treatment of Parkinson’s
Disease. CNS Drugs 29: 83–89, 2015.
Bronstein JM, Tagliati M, Alterman RL, Lozano AM, Volkmann J, 
Stefani A, Horak FB, Okun MS, Foote KD, Krack P, Pahwa R, 
Henderson JM, Hariz MI, Bakay RA, Rezai A, Marks WJ, Moro E, 
Vitek JL, Weaver FM, Gross RE, DeLong MR. Deep brain stimulation 
for Parkinson disease: an expert consensus and review of key issues. Arch
Neurol 68: 165, 2011.
Bronte-Stewart H, Barberini C, Koop MM, Hill BC, Henderson JM, 
Wingeier B. The STN beta-band profile in Parkinson’s disease is 
stationary and shows prolonged attenuation after deep brain stimulation. 
Exp Neurol 215: 20–28, 2009.
Brown P. Muscle sounds in Parkinson’s disease. The Lancet 349: 533–
535, 1997.
Brown P, Oliviero A, Mazzone P, Insola A, Tonali P, Lazzaro VD. 
Dopamine Dependency of Oscillations between Subthalamic Nucleus and
Pallidum in Parkinson’s Disease. J Neurosci 21: 1033–1038, 2001.
Brown P, Salenius S, Rothwell JC, Hari R. Cortical correlate of the 
Piper rhythm in humans. J Neurophysiol 80: 2911–2917, 1998.
Burn DJ, Rowan EN, Allan LM, Molloy S, O’Brien JT, McKeith IG. 
Motor subtype and cognitive decline in Parkinson’s disease, Parkinson’s 
disease with dementia, and dementia with Lewy bodies. J Neurol 
Neurosurg Psychiatry 77: 585–589, 2006.
Cao C, Li, Dianyou, Jiang, Tianxiao, Ince, Nuri Firat, Zhan, Shikun, 
Zhang, Jing, Sha, Zhiyi, Sun, Bomin. Resting state cortical oscillations 
of PD patients without and with Subthalamic deep brain stimulation, a 
MEG study. J. Clin. Neurophysiol 32:109–118, 2015.
Carlsson A. Treatment of Parkinson’s with L-DOPA. The early 
discovery phase, and a comment on current problems. J Neural Transm 
109: 777–787, 2002.
Caviness JN, Shill HA, Sabbagh MN, Evidente VGH, Hernandez JL, 
Adler CH. Corticomuscular coherence is increased in the small postural 
tremor of Parkinson’s disease. Mov Disord 21: 492–499, 2006.
74
Chen CC, Hsu YT, Chan HL, Chiou SM, Tu PH, Lee ST, Tsai CH, 
Lu CS, Brown P. Complexity of subthalamic 13–35 Hz oscillatory 
activity directly correlates with clinical impairment in patients with 
Parkinson’s disease. Exp Neurol 224: 234–240, 2010.
Connolly AT, Bajwa JA, Johnson MD. Cortical 
magnetoencephalography of deep brain stimulation for the treatment of 
postural tremor. Brain Stimulat 5: 616–624, 2012.
Connolly BS, Lang AE. Pharmacological treatment of parkinson disease:
A review. JAMA 311: 1670–1683, 2014.
Conway BA, Halliday DM, Farmer SF, Shahani U, Maas P, Weir AI, 
Rosenberg JR. Synchronization between motor cortex and spinal 
motoneuronal pool during the performance of a maintained motor task in 
man. J Physiol 489: 917–924, 1995.
DeLong MR. Primate models of movement disorders of basal ganglia 
origin. Trends Neurosci 13: 281–285, 1990.
DeLong MR. The Basal Gaglia. In: Kandel E, Schwartz J, Jessell T. 
Principles of Neural Science, Fourth Edition. McGraw-Hill 
Companies,Incorporated, 2000. p. 853–867.
Delwaide PJ, Pepin J-L, Pasqua VD, Noordhout AM de. Projections 
from basal ganglia to tegmentum: a subcortical route for explaining the 
pathophysiology of Parkinson’s disease signs? J Neurol 247: II75–II81, 
2000.
Deuschl G, Schade-Brittinger C, Krack P, Volkmann J, Schäfer H, 
Bötzel K, Daniels C, Deutschländer A, Dillmann U, Eisner W, Gruber
D, Hamel W, Herzog J, Hilker R, Klebe S, Kloss M, Koy J, Krause 
M, Kupsch A, Lorenz D, Lorenzl S, Mehdorn HM, Moringlane JR, 
Oertel W, Pinsker MO, Reichmann H, Reuss A, Schneider G-H, 
Schnitzler A, Steude U, Sturm V, Timmermann L, Tronnier V, 
Trottenberg T, Wojtecki L, Wolf E, Poewe W, Voges J, German 
Parkinson Study Group, Neurostimulation Section. A randomized trial
of deep-brain stimulation for Parkinson’s disease. N Engl J Med 355: 
896–908, 2006.
75
Drory VE, Inzelberg R, Groozman GB, Korczyn AD. N30 
somatosensory evoked potentials in patients with unilateral Parkinson’s 
disease. Acta Neurol Scand 97: 73–76, 1998.
Eggers C, Pedrosa DJ, Kahraman D, Maier F, Lewis CJ, Fink GR, 
Schmidt M, Timmermann L. Parkinson Subtypes Progress Differently 
in Clinical Course and Imaging Pattern. PLoS ONE 7: e46813, 2012.
Elberling C, Bak C, Kofoed B, Lebech J, Saermark K. Auditory 
magnetic fields from the human cerebral cortex: location and strength of 
an equivalent current dipole. Acta Neurol Scand 65: 553–569, 1982.
Eusebio A. Deep brain stimulation can suppress pathological 
synchronisation in parkinsonian patients. J Neurol Neurosurg Psychiatry 
82: 569–573, 2011.
Eusebio A, Cagnan H, Brown P. Does suppression of oscillatory 
synchronisation mediate some of the therapeutic effects of DBS in 
patients with Parkinson’s disease? Front Integr Neurosci 6: 47, 2012.
Fenoy AJ, Simpson RK. Management of device-related wound 
complications in deep brain stimulation surgery. J Neurosurg 116: 1324–
1332, 2012.
Ferreira JJ, Katzenschlager R, Bloem BR, Bonuccelli U, Burn D, 
Deuschl G, Dietrichs E, Fabbrini G, Friedman A, Kanovsky P, Kostic
V, Nieuwboer A, Odin P, Poewe W, Rascol O, Sampaio C, Schüpbach
M, Tolosa E, Trenkwalder C, Schapira A, Berardelli A, Oertel WH. 
Summary of the recommendations of the EFNS/MDS-ES review on 
therapeutic management of Parkinson’s disease. Eur J Neurol 20: 5–15, 
2013.
Fisher R, Salanova V, Witt T, Worth R, Henry T, Gross R, Oommen 
K, Osorio I, Nazzaro J, Labar D, Kaplitt M, Sperling M, Sandok E, 
Neal J, Handforth A, Stern J, DeSalles A, Chung S, Shetter A, Bergen
D, Bakay R, Henderson J, French J, Baltuch G, Rosenfeld W, 
Youkilis A, Marks W, Garcia P, Barbaro N, Fountain N, Bazil C, 
Goodman R, McKhann G, Babu Krishnamurthy K, Papavassiliou S, 
Epstein C, Pollard J, Tonder L, Grebin J, Coffey R, Graves N, the 
SANTE Study Group. Electrical stimulation of the anterior nucleus of 
thalamus for treatment of refractory epilepsy. Epilepsia 51: 899–908, 
2010.
76
Foffani G, Priori A, Egidi M, Rampini P, Tamma F, Caputo E, 
Moxon KA, Cerutti S, Barbieri S. 300- Hz subthalamic oscillations in 
Parkinson’s disease. Brain 126: 2153–2163, 2003.
Fogelson N, Kühn AA, Silberstein P, Limousin PD, Hariz M, 
Trottenberg T, Kupsch A, Brown P. Frequency dependent effects of 
subthalamic nucleus stimulation in Parkinson’s disease. Neurosci Lett 
382: 5–9, 2005.
Fogelson N, Williams D, Tijssen M, Bruggen G van, Speelman H, 
Brown P. Different Functional Loops between Cerebral Cortex and the 
Subthalmic Area in Parkinson’s Disease. Cereb Cortex 16: 64–75, 2006.
Follett KA, Torres-Russotto D. Deep brain stimulation of globus 
pallidus interna, subthalamic nucleus, and pedunculopontine nucleus for 
Parkinson’s disease: which target? Parkinsonism Relat Disord 18 Suppl 
1: S165–167, 2012.
Follett KA, Weaver FM, Stern M, Hur K, Harris CL, Luo P, Marks 
WJ, Rothlind J, Sagher O, Moy C, Pahwa R, Burchiel K, Hogarth P, 
Lai EC, Duda JE, Holloway K, Samii A, Horn S, Bronstein JM, 
Stoner G, Starr PA, Simpson R, Baltuch G, De Salles A, Huang GD, 
Reda DJ. Pallidal versus Subthalamic Deep-Brain Stimulation for 
Parkinson’s Disease. N Engl J Med 362: 2077–2091, 2010.
Forss N, Hari R, Salmelin R, Ahonen A, Hämäläinen M, Kajola M, 
Knuutila J, Simola J. Activation of the human posterior parietal cortex 
by median nerve stimulation. Exp Brain Res 99: 309–315, 1994a.
Forss N, Salmelin R, Hari R. Comparison of somatosensory evoked 
fields to airpuff and electric stimuli. Electroencephalogr Clin 
Neurophysiol 92: 510–517, 1994b.
Garcia L, Audin J, D’Alessandro G, Bioulac B, Hammond C. Dual 
Effect of High-Frequency Stimulation on Subthalamic Neuron Activity. J
Neurosci 23: 8743–8751, 2003.
Garcia L, D’Alessandro G, Bioulac B, Hammond C. High-frequency 
stimulation in Parkinson’s disease: more or less? Trends Neurosci 28: 
209–216, 2005.
77
Garcia PA, Aminoff MJ, Goodin DS. The frontal N30 component of the
median- derived SEP in patients with predominantly unilateral 
Parkinson’s disease. Neurology 45: 989–992, 1995.
Giannicola G. The effects of levodopa and ongoing deep brain 
stimulation on subthalamic beta oscillations in Parkinson’s disease. Exp 
Neurol 226: 120–127, 2010.
Goldman SM. Environmental Toxins and Parkinson’s Disease. Annu Rev
Pharmacol Toxicol 54: 141–164, 2014.
Gradinaru V, Mogri M, Thompson KR, Henderson JM, Deisseroth 
K. Optical deconstruction of parkinsonian neural circuitry. Science 324: 
354–359, 2009.
Gross J, Kujala J, Salmelin R, Schnitzler A. Noninvasive Functional 
Tomographic Connectivity Analysis with Magnetoencephalography. In: 
Hansen P, Kringelbach M, Salmelin R. MEG: An Introduction to 
Methods. Oxford University Press, 2010 p. 216–244.
Gross J, Tass PA, Salenius S, Hari R, Freund H-J, Schnitzler A. 
Cortico-muscular synchronization during isometric muscle contraction in 
humans as revealed by magnetoencephalography. J Physiol 527: 623–
631, 2000.
Grosse P, Cassidy MJ, Brown P. EEG–EMG, MEG–EMG and EMG–
EMG frequency analysis: physiological principles and clinical 
applications. Clin Neurophysiol 113: 1523–1531, 2002.
Hari R. On brain’s magnetic responses to sensory stimuli. J Clin 
Neurophysiol Off Publ Am Electroencephalogr Soc 8: 157–169, 1991.
Hari R, Forss N. Magnetoencephalography in the study of human 
somatosensory cortical processing. Philos Trans R Soc B Biol Sci 354: 
1145–1154, 1999.
Hari R, Parkkonen L, Nangini C. The brain in time: insights from 
neuromagnetic recordings. Ann N Y Acad Sci 1191: 89–109, 2010.
Hari R, Salenius S. Rhythmical corticomotor communication. 
Neuroreport 10: R1–10, 1999.
78
Hari R, Salmelin R, Mäkelä JP, Salenius S, Helle M. 
Magnetoencephalographic cortical rhythms. Int J Psychophysiol 26: 51–
62, 1997.
Hariz MI, Blomstedt P, Zrinzo L. Deep brain stimulation between 1947
and 1987: the untold story. Neurosurg Focus 29: E1, 2010.
Hely MA, Morris JGL, Traficante R, Reid WGJ, O’Sullivan DJ, 
Williamson PM. The Sydney multicentre study of Parkinson’s disease: 
progression and mortality at 10 years. J Neurol Neurosurg Psychiatry 67: 
300–307, 1999.
De Hemptinne C, Swann NC, Ostrem JL, Ryapolova-Webb ES, San 
Luciano M, Galifianakis NB, Starr PA. Therapeutic deep brain 
stimulation reduces cortical phase-amplitude coupling in Parkinson’s 
disease. Nat Neurosci 18: 779–786, 2015.
Hirschmann J, Özkurt TE, Butz M, Homburger M, Elben S, 
Hartmann CJ, Vesper J, Wojtecki L, Schnitzler A. Distinct oscillatory 
STN-cortical loops revealed by simultaneous MEG and local field 
potential recordings in patients with Parkinson’s disease. NeuroImage 55:
1159–1168, 2011.
Hirschmann J, Özkurt TE, Butz M, Homburger M, Elben S, 
Hartmann CJ, Vesper J, Wojtecki L, Schnitzler A. Differential 
modulation of STN-cortical and cortico-muscular coherence by 
movement and levodopa in Parkinson’s disease. NeuroImage 68: 203–
213, 2013.
Hobson P, Meara J, Ishihara-Paul L. The estimated life expectancy in a
community cohort of Parkinson’s disease patients with and without 
dementia, compared with the UK population. J Neurol Neurosurg 
Psychiatry 81: 1093–1098, 2010.
Holsheimer J, Demeulemeester H, Nuttin B, De Sutter P. 
Identification of the target neuronal elements in electrical deep brain 
stimulation. Eur J Neurosci 12: 4573–4577, 2000.
Hämäläinen M, Hari R, Ilmoniemi RJ, Knuutila J, Lounasmaa OV. 
Magnetoencephalography–theory, instrumentation, and applications to 
noninvasive studies of the working human brain. Rev Mod Phys 65: 413–
497, 1993.
79
Insola A, Rossi S, Mazzone P, Pasqualetti P. Parallel processing of 
sensory inputs: an evoked potentials study in Parkinsonian patients 
implanted with thalamic stimulators. Clin Neurophysiol 110: 146–151, 
1999.
Jech R, Mueller K, Urgošík D, Sieger T, Holiga Š, Růžička F, Dušek 
P, Havránková P, Vymazal J, Růžička E. The subthalamic microlesion 
story in Parkinson’s disease: electrode insertion-related motor 
improvement with relative cortico-subcortical hypoactivation in fMRI. 
PloS One 7: e49056, 2012.
Jensen O, Vanni S. A New Method to Identify Multiple Sources of 
Oscillatory Activity from Magnetoencephalographic Data. NeuroImage 
15: 568–574, 2002.
Johnson AN, Wheaton LA, Shinohara M. Attenuation of 
corticomuscular coherence with additional motor or non-motor task. Clin 
Neurophysiol 122: 356–363, 2011.
Kaasinen V, Vahlberg T, Suominen S. Increasing age-adjusted male-to-
female incidence ratio of Parkinson’s disease. Mov Disord 30: 286–288, 
2015.
Kilner JM, Baker SN, Salenius S, Hari R, Lemon RN. Human Cortical
Muscle Coherence Is Directly Related to Specific Motor Parameters. J 
Neurosci 20: 8838–8845, 2000.
Kleiner-Fisman G, Herzog J, Fisman DN, Tamma F, Lyons KE, 
Pahwa R, Lang AE, Deuschl G. Subthalamic nucleus deep brain 
stimulation: summary and meta-analysis of outcomes. Mov Disord Off J 
Mov Disord Soc 21 Suppl 14: S290–304, 2006.
Krack P, Batir A, Van Blercom N, Chabardes S, Fraix V, Ardouin C, 
Koudsie A, Limousin PD, Benazzouz A, LeBas JF, Benabid A-L, 
Pollak P. Five-Year Follow-up of Bilateral Stimulation of the 
Subthalamic Nucleus in Advanced Parkinson’s Disease. N Engl J Med 
349: 1925–1934, 2003.
Krause V, Wach C, Südmeyer M, Ferrea S, Schnitzler A, Pollok B. 
Cortico-muscular coupling and motor performance are modulated by 20 
Hz transcranial alternating current stimulation (tACS) in Parkinson’s 
disease. Front Hum Neurosci 7, 2014.
80
Kringelbach ML, Jenkinson N, Owen SLF, Aziz TZ. Translational 
principles of deep brain stimulation. Nat Rev Neurosci 8: 623–635, 2007.
Kristeva-Feige R, Fritsch C, Timmer J, Lücking C-H. Effects of 
attention and precision of exerted force on beta range EEG-EMG 
synchronization during a maintained motor contraction task. Clin 
Neurophysiol 113: 124–131, 2002.
Kristeva R, Patino L, Omlor W. Beta-range cortical motor spectral 
power and corticomuscular coherence as a mechanism for effective 
corticospinal interaction during steady-state motor output. NeuroImage 
36: 785–792, 2007.
Kühn AA, Kupsch A, Schneider G-H, Brown P. Reduction in 
subthalamic 8-35 Hz oscillatory activity correlates with clinical 
improvement in Parkinson’s disease. Eur J Neurosci 23: 1956–1960, 
2006.
Kühn AA, Williams D, Kupsch A, Limousin P, Hariz M, Schneider 
G-H, Yarrow K, Brown P. Event- related beta desynchronization in 
human subthalamic nucleus correlates with motor performance. Brain 
127: 735–746, 2004.
Kuopio A-M, Marttila RJ, Helenius H, Rinne UK. Changing 
epidemiology of Parkinson’s disease in southwestern Finland. Neurology 
52: 302–302, 1999.
Laitinen L. Surgical treatment, past and present, in Parkinson’s disease. 
Acta Neurol Scand Suppl 51: 43–58, 1972.
De Lau LM, Breteler MM. Epidemiology of Parkinson’s disease. 
Lancet Neurol 5: 525–535, 2006.
De Lau LML, Verbaan D, Marinus J, van Hilten JJ. Survival in 
Parkinson’s disease. Relation with motor and non-motor features. 
Parkinsonism Relat Disord 20: 613–616, 2014.
Laxton AW, Tang-Wai DF, McAndrews MP, Zumsteg D, Wennberg 
R, Keren R, Wherrett J, Naglie G, Hamani C, Smith GS, Lozano AM.
A phase I trial of deep brain stimulation of memory circuits in 
Alzheimer’s disease. Ann Neurol 68: 521–534, 2010.
81
De Letter M, Aerts A, Van Borsel J, Vanhoutte S, De Taeye L, Raedt 
R, van Mierlo P, Boon P, Van Roost D, Santens P. 
Electrophysiological registration of phonological perception in the 
subthalamic nucleus of patients with Parkinson’s Disease. Brain Lang 
138: 19–26, 2014.
Levy RM, Lamb S, Adams JE. Treatment of chronic pain by deep brain 
stimulation: long term follow-up and review of the literature. 
Neurosurgery 21: 885–893, 1987.
Li Q, Ke Y, Chan DCW, Qian Z-M, Yung KKL, Ko H, Arbuthnott 
GW, Yung W-H. Therapeutic Deep Brain Stimulation in Parkinsonian 
Rats Directly Influences Motor Cortex. Neuron 76: 1030–1041, 2012.
Lim M, Kim JS, Chung CK. Oscillatory interaction between the hand 
area of human primary motor cortex and finger muscles during steady-
state isometric contraction. Clin Neurophysiol Off J Int Fed Clin 
Neurophysiol 122: 2246–2253, 2011.
Limousin P, Pollak P, Benazzouz A, Hoffmann D, Le Bas J-F, Perret 
JE, Benabid A-L, Broussolle E. Effect on parkinsonian signs and 
symptoms of bilateral subthalamic nucleus stimulation. The Lancet 345: 
91–95, 1995.
Little S, Pogosyan A, Neal S, Zavala B, Zrinzo L, Hariz M, Foltynie 
T, Limousin P, Ashkan K, FitzGerald J, Green AL, Aziz TZ, Brown 
P. Adaptive deep brain stimulation in advanced Parkinson disease. Ann 
Neurol 74: 449–457, 2013.
Litvak V, Eusebio A, Jha A, Oostenveld R, Barnes G, Foltynie T, 
Limousin P, Zrinzo L, Hariz MI, Friston K, Brown P. Movement-
related changes in local and long-range synchronization in Parkinson’s 
disease revealed by simultaneous magnetoencephalography and 
intracranial recordings. J Neurosci Off J Soc Neurosci 32: 10541–10553, 
2012.
Litvak V, Eusebio A, Jha A, Oostenveld R, Barnes GR, Penny WD, 
Zrinzo L, Hariz MI, Limousin P, Friston KJ, Brown P. Optimized 
beamforming for simultaneous MEG and intracranial local field potential 
recordings in deep brain stimulation patients. NeuroImage 50: 1578–
1588, 2010.
82
Litvak V, Jha A, Eusebio A, Oostenveld R, Foltynie T, Limousin P, 
Zrinzo L, Hariz MI, Friston K, Brown P. Resting oscillatory cortico-
subthalamic connectivity in patients with Parkinson’s disease. Brain J 
Neurol 134: 359–374, 2011.
Lopes da Silva FH. Electrophysiological Basis of MEG Signals. In: 
Hansen P, Kringelbach M, Salmelin R. MEG: An Introduction to 
Methods. Oxford University Press, 2010 p.1–23.
Macleod AD, Taylor KSM, Counsell CE. Mortality in Parkinson’s 
disease: A systematic review and meta-analysis. Mov Disord 29: 1615–
1622, 2014.
Mamikonyan E, Siderowf AD, Duda JE, Potenza MN, Horn S, Stern 
MB, Weintraub D. Long-Term Follow-Up of Impulse Control Disorders 
in Parkinson’s Disease. Mov Disord Off J Mov Disord Soc 23: 75–80, 
2008.
Marsden JF, Limousin-Dowsey P, Ashby P, Pollak P, Brown P. 
Subthalamic nucleus, sensorimotor cortex and muscle interrelationships 
in Parkinson’s disease. Brain 124: 378–388, 2001.
Marttila RJ, Rinne UK, Marttila RJ. Progression and survival in 
Parkinson’s disease. Acta Neurol Scand 84: 24–28, 1991.
Mauguière F, Merlet I, Forss N, Vanni S, Jousmäki V, Adeleine P, 
Hari R. Activation of a distributed somatosensory cortical network in the 
human brain: a dipole modelling study of magnetic fields evoked by 
median nerve stimulation. Part II: Effects of stimulus rate, attention and 
stimulus detection. Electroencephalogr Clin Neurophysiol 104: 290–295, 
1997.
McClelland VM, Cvetkovic Z, Mills KR. Rectification of the EMG is 
an unnecessary and inappropriate step in the calculation of 
Corticomuscular coherence. J Neurosci Methods 205: 190–201, 2012.
McIntyre CC, Grill WM. Excitation of central nervous system neurons 
by nonuniform electric fields. Biophys J 76: 878–888, 1999.
McIntyre CC, Savasta M, Kerkerian-Le Goff L, Vitek JL. Uncovering
the mechanism(s) of action of deep brain stimulation: activation, 
inhibition, or both. Clin Neurophysiol 115: 1239–1248, 2004.
83
Medvedovsky M, Taulu S, Bikmullina R, Ahonen A, Paetau R. Fine 
tuning the correlation limit of spatio-temporal signal space separation for 
magnetoencephalography. J Neurosci Methods 177: 203–211, 2009.
Mendez-Balbuena I, Huethe F, Schulte-Mönting J, Leonhart R, 
Manjarrez E, Kristeva R. Corticomuscular coherence reflects 
interindividual differences in the state of the corticomuscular network 
during low-level static and dynamic forces. Cereb Cortex N Y N 1991 22: 
628–638, 2012.
Miocinovic S, Somayajula S, Chitnis S, Vitek JL. History, 
Applications, and Mechanisms of Deep Brain Stimulation. JAMA Neurol 
70: 163–71, 2013.
Montgomery Jr EB, Gale JT. Mechanisms of action of deep brain 
stimulation (DBS). Neurosci Biobehav Rev 32: 388–407, 2008.
Moreau C, Defebvre L, Destée A, Bleuse S, Clement F, Blatt JL, 
Krystkowiak P, Devos D. STN-DBS frequency effects on freezing of 
gait in advanced Parkinson disease. Neurology 71: 80–84, 2008.
Myers LJ, Lowery M, O’Malley M, Vaughan CL, Heneghan C, St 
Clair Gibson A, Harley YXR, Sreenivasan R. Rectification and non-
linear pre-processing of EMG signals for cortico-muscular analysis. J 
Neurosci Methods 124: 157–165, 2003.
Mäkelä JP. Bioelectric Measurements: Magnetoencephalography. In: 
Brahme A. Comprehensive Biomedical Physics. Elsevier, Amsterdam, 
2014 p. 47–72. 
Mäkelä J, Hari R. Long-latency auditory evoked magnetic fields. Adv 
Neurol 54: 177–191, 1990.
Mäkelä JP, Hari R, Karhu J, Salmelin R, Teräväinen H. Suppression 
of magnetic μ rhythm during parkinsonian tremor. Brain Res 617: 189–
193, 1993.
Nambu A, Tokuno H, Takada M. Functional significance of the cortico-
subthalamo-pallidal “hyperdirect” pathway. Neurosci Res 43: 111–117, 
2002.
84
Naskar S, Sood SK, Goyal V. Effect of acute deep brain stimulation of 
the subthalamic nucleus on auditory event-related potentials in 
Parkinson’s disease. Parkinsonism Relat Disord 16: 256–260, 2010.
Neto OP, Christou EA. Rectification of the EMG signal impairs the 
identification of oscillatory input to the muscle. J Neurophysiol 103: 
1093–1103, 2010.
Olanow CW, Brundin P. Parkinson’s Disease and Alpha Synuclein: Is 
Parkinson’s Disease a Prion-Like Disorder? Mov Disord 28: 31–40, 2013.
Olanow CW, Kieburtz K, Odin P, Espay AJ, Standaert DG, 
Fernandez HH, Vanagunas A, Othman AA, Widnell KL, Robieson 
WZ, Pritchett Y, Chatamra K, Benesh J, Lenz RA, Antonini A, LCIG
Horizon Study Group. Continuous intrajejunal infusion of levodopa-
carbidopa intestinal gel for patients with advanced Parkinson’s disease: a 
randomised, controlled, double-blind, double-dummy study. Lancet 
Neurol 13: 141–149, 2014.
Oosterveld LP, Allen Jr. JC, Reinoso G, Seah S-H, Tay K-Y, Au W-
L, Tan LCS. Prognostic factors for early mortality in Parkinson’s 
disease. Parkinsonism Relat Disord 21: 226–230, 2015.
Østergaard K, Sunde N, Dupont E. Effects of bilateral stimulation of 
the subthalamic nucleus in patients with severe Parkinson’s disease and 
motor fluctuations. Mov Disord Off J Mov Disord Soc 17: 693–700, 2002.
Park H, Kim JS, Paek SH, Jeon BS, Lee JY, Chung CK. Cortico-
muscular coherence increases with tremor improvement after deep brain 
stimulation in Parkinsonʼs disease: NeuroReport 20: 1444–1449, 2009.
Pekkonen E, Ahveninen J, Virtanen J, Teräväinen H. Parkinson’s 
disease selectively impairs preattentive auditory processing: an MEG 
study. Neuroreport 9: 2949–2952, 1998.
Perez-Lloret S. Prevalence and Pharmacological Factors Associated 
With Impulse-Control Disorder Symptoms in Patients With Parkinson 
Disease. Clin Neuropharmacol 35: 261–265, 2012.
Pierantozzi M, Mazzone P, Bassi A, Rossini PM, Peppe A, Altibrandi 
MG, Stefani A, Bernardi G, Stanzione P. The effect of deep brain 
stimulation on the frontal N30 component of somatosensory evoked 
85
potentials in advanced Parkinson’s disease patients. Clin Neurophysiol 
Off J Int Fed Clin Neurophysiol 110: 1700–1707, 1999.
Piitulainen H, Bourguignon M, De Tiège X, Hari R, Jousmäki V. 
Coherence between magnetoencephalography and hand-action-related 
acceleration, force, pressure, and electromyogram. NeuroImage 72: 83–
90, 2013a.
Piitulainen H, Bourguignon M, De Tiège X, Hari R, Jousmäki V. 
Corticokinematic coherence during active and passive finger movements. 
Neuroscience 238: 361–370, 2013b.
Poewe WH, Rascol O, Quinn N, Tolosa E, Oertel WH, Martignoni E, 
Rupp M, Boroojerdi B, SP 515 Investigators. Efficacy of pramipexole 
and transdermal rotigotine in advanced Parkinson’s disease: a double-
blind, double-dummy, randomised controlled trial. Lancet Neurol 6: 513–
520, 2007.
Pogosyan A, Gaynor LD, Eusebio A, Brown P. Boosting Cortical 
Activity at Beta-Band Frequencies Slows Movement in Humans. Curr 
Biol 19: 1637–1641, 2009.
Pohja M, Salenius S, Hari R. Reproducibility of cortex–muscle 
coherence. NeuroImage 26: 764–770, 2005.
Pollok B, Gross J, Dirks M, Timmermann L, Schnitzler A. The 
cerebral oscillatory network of voluntary tremor. J Physiol 554: 871–878,
2004.
Pollok B, Krause V, Martsch W, Wach C, Schnitzler A, Südmeyer M.
Motor-cortical oscillations in early stages of Parkinson’s disease. J 
Physiol 590: 3203–3212, 2012.
Pringsheim T, Jette N, Frolkis A, Steeves TDL. The prevalence of 
Parkinson’s disease: A systematic review and meta-analysis. Mov Disord 
29: 1583–1590, 2014.
Priori A, Cinnante C, Genitrini S, Pesenti A, Tortora G, Bencini C, 
Barelli MV, Buonamici V, Carella F, Girotti F, Soliveri P, Magrini F, 
Morganti A, Albanese A, Broggi S, Scarlato G, Barbieri S. Non-motor
effects of deep brain stimulation of the subthalamic nucleus in 
86
Parkinson’s disease: preliminary physiological results. Neurol Sci Off J 
Ital Neurol Soc Ital Soc Clin Neurophysiol 22: 85–86, 2001.
Priori A, Foffani G, Pesenti A, Tamma F, Bianchi AM, Pellegrini M, 
Locatelli M, Moxon KA, Villani RM. Rhythm-specific pharmacological
modulation of subthalamic activity in Parkinson’s disease. Exp Neurol 
189: 369–379, 2004.
Puschmann A. Monogenic Parkinson’s disease and parkinsonism: 
clinical phenotypes and frequencies of known mutations. Parkinsonism 
Relat Disord 19: 407–415, 2013.
Rasche D, Rinaldi PC, Young RF, Tronnier VM. Deep brain 
stimulation for the treatment of various chronic pain syndromes. 
Neurosurg Focus 21: E8, 2006.
Remple MS, Bradenham CH, Kao CC, Charles PD, Neimat JS, 
Konrad PE. Subthalamic nucleus neuronal firing rate increases with 
Parkinson’s disease progression. Mov Disord Off J Mov Disord Soc 26: 
1657–1662, 2011.
Rosin B, Slovik M, Mitelman R, Rivlin-Etzion M, Haber SN, Israel Z,
Vaadia E, Bergman H. Closed-loop deep brain stimulation is superior in 
ameliorating parkinsonism. Neuron 72: 370–384, 2011.
Rossi L, Marceglia S, Foffani G, Cogiamanian F, Tamma F, Rampini 
P, Barbieri S, Bracchi F, Priori A. Subthalamic local field potential 
oscillations during ongoing deep brain stimulation in Parkinson’s disease.
Brain Res Bull 76: 512–521, 2008.
Rossini PM, Babiloni F, Bernardi G, Cecchi L, Johnson PB, 
Malentacca A, Stanzione P, Urbano A. Abnormalities of short-latency 
somatosensory evoked potentials in parkinsonian patients. 
Electroencephalogr Clin Neurophysiol Potentials Sect 74: 277–289, 
1989.
Salenius S, Avikainen S, Kaakkola S, Hari R, Brown P. Defective 
cortical drive to muscle in Parkinson’s disease and its improvement with 
levodopa. Brain 125: 491–500, 2002.
87
Salmelin R, Hari R. Spatiotemporal characteristics of sensorimotor 
neuromagnetic rhythms related to thumb movement. Neuroscience 60: 
537–550, 1994.
Schiefer TKMD, Matsumoto JYMD, Lee KH. Moving forward: 
advances in the treatment of movement disorders with deep brain 
stimulation. Front Integr Neurosci 5: 69, 2011.
Schnitzler A, Timmermann L, Gross J. Physiological and pathological 
oscillatory networks in the human motor system. J Physiol Paris 99: 3–7, 
2006.
Schuepbach WMM, Rau J, Knudsen K, Volkmann J, Krack P, 
Timmermann L, Hälbig TD, Hesekamp H, Navarro SM, Meier N, 
Falk D, Mehdorn M, Paschen S, Maarouf M, Barbe MT, Fink GR, 
Kupsch A, Gruber D, Schneider G-H, Seigneuret E, Kistner A, 
Chaynes P, Ory-Magne F, Brefel Courbon C, Vesper J, Schnitzler A, 
Wojtecki L, Houeto J-L, Bataille B, Maltête D, Damier P, Raoul S, 
Sixel-Doering F, Hellwig D, Gharabaghi A, Krüger R, Pinsker MO, 
Amtage F, Régis J-M, Witjas T, Thobois S, Mertens P, Kloss M, 
Hartmann A, Oertel WH, Post B, Speelman H, Agid Y, Schade-
Brittinger C, Deuschl G. Neurostimulation for Parkinson’s Disease with 
Early Motor Complications. N Engl J Med 368: 610–622, 2013.
Schulz JB, Falkenburger BH. Neuronal pathology in Parkinson’s 
disease. Cell Tissue Res 318: 135–147, 2004.
Seppi K, Weintraub D, Coelho M, Perez-Lloret S, Fox SH, 
Katzenschlager R, Hametner E-M, Poewe W, Rascol O, Goetz CG, 
Sampaio C. The Movement Disorder Society Evidence-Based Medicine 
Review Update: Treatments for the Non-Motor Symptoms of Parkinson’s 
Disease. Mov Disord Off J Mov Disord Soc 26: S42–S80, 2011.
Siegfried J, Lippitz B. Bilateral chronic electrostimulation of 
ventroposterolateral pallidum: a new therapeutic approach for alleviating 
all parkinsonian symptoms. Neurosurgery 35: 1126–1129; discussion 
1129–1130, 1994.
Soikkeli R, Partanen J, Soininen H, Pääkkönen A, Riekkinen Sr. P. 
Slowing of EEG in Parkinson’s disease. Electroencephalogr Clin 
Neurophysiol 79: 159–165, 1991.
88
Spiegel EA, Wycis HT, Marks M, Lee AJ. Stereotaxic Apparatus for 
Operations on the Human Brain. Science 106: 349–350, 1947.
Sturm V, Lenartz D, Koulousakis A, Treuer H, Herholz K, Klein JC, 
Klosterkötter J. The nucleus accumbens: a target for deep brain 
stimulation in obsessive-compulsive- and anxiety-disorders. J Chem 
Neuroanat 26: 293–299, 2003.
Taulu S, Kajola M. Presentation of electromagnetic multichannel data: 
The signal space separation method. J Appl Phys 97: 124905, 2005.
Taulu S, Simola J. Spatiotemporal signal space separation method for 
rejecting nearby interference in MEG measurements. Phys Med Biol 51: 
1759–1768, 2006.
Taulu S, Simola J, Kajola M. Applications of the Signal Space 
Separation Method. IEEE Trans Signal Process 53: 3359–3372, 2005.
Temperli P, Ghika J, Villemure J-G, Burkhard PR, Bogousslavsky J, 
Vingerhoets FJG. How do parkinsonian signs return after 
discontinuation of subthalamic DBS? Neurology 60: 78–81, 2003.
Timmermann L, Gross J, Dirks M, Volkmann J, Freund H-J, 
Schnitzler A. The cerebral oscillatory network of parkinsonian resting 
tremor. Brain 126: 199–212, 2003.
Timmermann L, Wojtecki L, Gross J, Lehrke R, Voges J, Maarouf 
M, Treuer H, Sturm V, Schnitzler A. Ten-Hertz stimulation of 
subthalamic nucleus deteriorates motor symptoms in Parkinson’s disease. 
Mov Disord Off J Mov Disord Soc 19: 1328–1333, 2004.
Ushiyama J, Takahashi Y, Ushiba J. Muscle dependency of 
corticomuscular coherence in upper and lower limb muscles and training-
related alterations in ballet dancers and weightlifters. J Appl Physiol 
Bethesda Md 1985 109: 1086–1095, 2010.
Uutela K, Hämäläinen M, Somersalo E. Visualization of 
Magnetoencephalographic Data Using Minimum Current Estimates. 
NeuroImage 10: 173–180, 1999.
Volkmann J, Joliot M, Mogilner A, Ioannides AA, Lado F, Fazzini E, 
Ribary U, Llinas R. Central motor loop oscillations in parkinsonian 
89
resting tremor revealed magnetoencephalography. Neurology 46: 1359–
1359, 1996.
Walker HC, Huang H, Gonzalez CL, Bryant JE, Killen J, Knowlton 
RC, Montgomery EB, Cutter GC, Yildirim A, Guthrie BL, Watts RL.
Short latency activation of cortex by clinically effective thalamic brain 
stimulation for tremor. Mov Disord 27: 1404–1412, 2012.
Weaver FM, Follett K, Stern M, Hur K, Harris C, Marks WJ, 
Rothlind J, Sagher O, Reda D, Moy CS, Pahwa R, Burchiel K, 
Hogarth P, Lai EC, Duda JE, Holloway K, Samii A, Horn S, 
Bronstein J, Stoner G, Heemskerk J, Huang GD, CSP 468 Study 
Group. Bilateral deep brain stimulation vs best medical therapy for 
patients with advanced Parkinson disease: a randomized controlled trial. 
JAMA 301: 63–73, 2009.
Weiss D, Breit S, Hoppe J, Hauser A-K, Freudenstein D, Krüger R, 
Sauseng P, Govindan RB, Gerloff C. Subthalamic nucleus stimulation 
restores the efferent cortical drive to muscle in parallel to functional 
motor improvement. Eur J Neurosci 35: 896–908, 2012.
Whitmer D, de Solages C, Hill B, Yu H, Henderson JM, Bronte-
Stewart H. High frequency deep brain stimulation attenuates subthalamic
and cortical rhythms in Parkinson’s disease. Front Hum Neurosci 6, 2012.
Willis AW, Schootman M, Kung N, Evanoff BA, Perlmutter JS, 
Racette BA. PRedictors of survival in patients with parkinson disease. 
Arch Neurol 69: 601–607, 2012.
Witham CL, Riddle CN, Baker MR, Baker SN. Contributions of 
descending and ascending pathways to corticomuscular coherence in 
humans. J Physiol 589: 3789–3800, 2011.
Zaidel A, Spivak A, Grieb B, Bergman H, Israel Z. Subthalamic span 
of β oscillations predicts deep brain stimulation efficacy for patients with 
Parkinson’s disease. Brain 133: 2007–2021, 2010.
Zrinzo L, Foltynie T, Limousin P, Hariz MI. Reducing hemorrhagic 
complications in functional neurosurgery: a large case series and 
systematic literature review. J Neurosurg 116: 84–94, 2012.
90
